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Dorsal root ganglion (DRG) neurones perceive and discriminate diverse types 
of sensations. Nociceptors are a subgroup of DRG neurones specialised in 
translating noxious pain stimuli to the spinal cord and higher brain centres. 
Following a noxious insult, nociceptors are known to have enhanced 
excitability and peptide secretion both of which, are likely to be a consequence 
of increased membrane trafficking and vesicle fusion with the plasma 
membrane. Vesicle-associated membrane proteins (VAMPs) are vesicular 
SNARE proteins (v-SNAREs) which complex together with cognate target 
SNARE proteins (t-SNAREs) found on ‘acceptor’ compartments. Together 
they regulate membrane trafficking and vesicle fusion; while much is known 
about the v- and t-SNAREs involved in the fusion of neurotransmitter and 
neuropeptide-containing vesicles with the plasma membrane, to date the 
identity of SNAREs involved in ion channel trafficking or secretion in 
nociceptors is limited.   
 
To explore the role of SNAREs on DRG neurones’ secretion and excitability, 
an in vitro inflammation model was established. An inflammatory soup 
containing ATP, bradykinin, prostaglandin E2, histamine, noradrenaline, nerve 
growth factor, and serotonin was added for 22 h. This incubation induced 
hyperexcitability. In voltage-clamp, sodium currents resistant to tetrodotoxin, 
Nav1.9 and Nav1.8 currents, were increased. However, a decrease in the 
expression of Nav1.7 (TTX-sensitive) and Nav1.9 (TTX-resistant) at the 
plasma membrane was observed, which likely reflects changes in subcellular 
location of these channels induced by the inflammatory model. This study also 
identified the expression of seven vesicle membrane-associated proteins in 
DRG neurones (VAMP1-5, 7 and 8). This expression was found across all 
soma diameters. VAMP1/2/7 were observed in the neurites. The potential of 
the botulinum chimaeras, tetbot A and tetbot B, in reducing CGRP (calcitonin 
gene-related peptide) release and preventing excitability induced by an 
inflammatory soup was also explored. These chimaeras are designed to target 
isolectin B4-negative DRG neurones and cleave SNAP25 (t-SNARE) and 
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VAMP1/2/3 (v-SNAREs). Tetbot A cleaved SNAP25 and significantly reduced 
CGRP release elicited by 60 mM KCl. The interpretation of the 
electrophysiology results is problematic as the detergent used in the chimaera 
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1 - General introduction 
 
1.1 Why study pain? 
The ability to translate the world that surrounds us into electrochemical 
information gives us the opportunity to react to environmental changes crucial 
to our survival. Pain signalling is one of such survival mechanisms built to alert 
us and to aid in tissue recovery. Dorsal root ganglion (DRG) neurones are part 
of this mechanism in the peripheral nervous system. They innervate our skin 
and viscera detecting and transducing signals such as heat, cold, pressure, 
and noxious stimuli to the spinal cord. Nociceptors are a subgroup of DRG 
neurones, specialised in pain signalling and the detectors of noxious stimuli. 
Hence, noxious stimuli such as extreme heat elicit pain signals via nociceptors 
that ultimately generate the complex sensation of feeling pain.   
 
By definition, (acute) pain is the transitory sensory and emotional experience 
with actual or potential tissue damage. Pain signals may persist for weeks, 
months or years (chronic pain) without an identifiable cause (Costigan, Scholz 
and Woolf 2009). Chronic pain affects 43.5% of the adult British population, 
and it represents a severe emotional and physical burden for the individual but 
also for society (Fayaz et al. 2016). Current drug therapies are often 
ineffective, common analgesics are short-acting and cause adverse side 
effects which raise severe problems for repeated usage (Dolly and O'Connell 
2012). For instance, the recent increase in opioid prescriptions has caused an 
opioid overdose crisis in the USA (Volkow and Collins 2017). Hence, an 
improvement of the current understanding of the pathophysiology of pain is 
essential not only to improve diagnosis but for the development of specific drug 
therapy that matches this unmet clinical need. 
 
1.2 Nociceptor overview 
First descriptions of specialised noxious stimulus detectors, nociceptors, were 
made by Charles Sherrington, “there is considerable evidence that the skin is 
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provided with a set of nerve-endings whose specific office it is to be amenable 
to stimuli that do the skin injury […] preferably termed nocicepient […].” 
(Sherrington 1903). Nociceptors are characterised by having a high threshold 
and by responding to multiple energy forms (thermal, mechanical and 
chemical). Different groups have shown that nociceptors may be subdivided 
according to distinct response characteristics, molecular markers, modalities 
of stimulation and soma diameter (Lawson and Waddell 1991, Stucky and 
Lewin 1999, Slugg, Meyer and Campbell 2000).  
 
1.2.1 Fibre groups 
There are four afferent fibre groups - Aa, Ab, Ad and C - and nociceptors are 
considered to be either Ad- or C-fibres. Together they are thought to innervate 
skin and viscera, and mediate proprioception, mechanoception, nociception, 
thermoception and pruriception. In addition to having different sensor 
transducers they also end at different lamina in the spinal cord (Figure 1.1). 
 
 
Figure 1.1 The Aa, Ab, Ad and C fibres terminate at different lamina. 
DRG neurones innervating muscle spindles (spindles), golgi tendon organs (GTO), skin and 
viscera terminate at different lamina (I to V, and VII to IX). These relay proprioception, 
mechanoception, nociception, thermoception or pruriception information from the peripheral 
terminals. (Taken from Lallemend and Ernfors 2012) 
 
1.2.2 Response characteristics 
The response of Ad- or C-nociceptors diverge in impulse propagation speed 
and this is due to myelination of the afferents. Myelination saves energy by 
restricting the action potentials to the nodes of Ranvier and enabling fast 
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saltatory impulse propagation. It has been shown that nociceptor Ad-fibers are 
myelinated whereas nociceptor C-fibers are not. Hence, Ad-fibers have faster 
impulse propagation when compared to C-fibers (Harper and Lawson 1985a, 
Harper and Lawson 1985b). Other studies have further characterised 
nociceptors according to their action potential configuration. The presence or 
absence of a inflection on repolarisation phase is an indicator of myelinated 
fibers (Fulton 1987). This inflection is the consequence of inward current 
carried out by Na+ and Ca2+ while in the absence of the inflection is Na+ 
(Gallego and Eyzaguirre 1978, Scott and Edwards 1980, Yoshida, Matsuda 
and Samejima 1978). Nociceptors are unique in their set of voltage-gated 
sodium channels (VGSCs) and their expression directly affects many of their 
electrophysiological properties and underlying excitability (Elliott and Elliott 
1993). 
 
1.2.3 Molecular markers 
By responding to multiple energy forms nociceptors are equipped with a wide 
arrange of receptors and ion channels but they can be divided in two major 
neurochemical subtypes, peptidergic and non-peptidergic.  
 
• Peptidergic neurones contain calcitonin-gene related neuropeptide 
(CGRP), substance P, and somatostatin. 
• Non-peptidergic lack neuropeptides but contain fluoride-resistant acid 
phosphatase activity (FRAP) and bind plant lectin isolectin B4 (IB4) 
(Nagy and Hunt 1982, Silverman and Kruger 1988a, Silverman and 
Kruger 1988b).  
 
IB4 belongs to a group of plant proteins, lectins, that bind to the carbohydrate 
portion of glycoproteins and glycolipids (Barondes 1988). IB4 binding has been 
used for further characterisation of these two subpopulations and it has shown 
that these two subtypes have distinct electrophysiological properties (Stucky 
and Lewin 1999, Choi, Dib-Hajj and Waxman 2007), are regulated by different 
neurotrophic factors – IB4-positive by glial-derived neurotrophic factor (GDNF) 
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and IB4-negative by nerve growth factor (NGF) – (Bennett et al. 1998, Molliver 
et al. 1997),  and terminate at different regions in the spinal cord (Coimbra, 
Sodrebor.Bp and Magalhaes 1974, Silverman and Kruger 1990).  
 
The peptidergic subpopulation of DRG neurones may also be identified by 
peripherin (Goldstein, House and Gainer 1991). Peripherin is an intermediate 
filament protein named after it being found on ‘periphery reaching’ neurones 
(Greene 1989). Peripherin-positive DRG neurones have been found to have 
predominantly a small diameter and 87% express substance P and 43% 
express CGRP(Goldstein et al. 1991).  
 
1.2.4 Modalities of stimulation 
Earlier studies of primary afferents used microneurography to assess the 
different modalities of stimulation (Meyer and Campbell 1988, Davis, Meyer 
and Campbell 1993, Treede et al. 1995). This has led to the classification of 
primary afferents as mechanically sensitive afferents (MSA) or mechanically 
insensitive afferents (MIA)(Meyer et al. 1991). In addition, it was used to 
describe further properties such as heat sensitivity, fiber sensitization and 
importantly hyperalgesia (Meyer et al. 1991, Treede et al. 1992). 
 
1.2.5 Soma diameter 
Nociceptors have been demonstrated to have a small mean diameter 
compared to other primary afferent fibres (Lawson and Waddell 1991). 
Specifically, small (< 17 µm), intermediate (17-25 µm) and large (> 25 µm).  
Although it varies slightly between mice and rats. Yet, recent molecular biology 
approaches to DRG classification are challenging this reference.  
 
1.2.6 other classifications 
During the course of this project several molecular biology approaches 
reclassified DRG neurones (Chiu et al. 2014, Thakur et al. 2014, Usoskin et 
al. 2015, Rouwette et al. 2016a). Using single cell RNA-seq Usoskin et al 
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unbiasedly grouped DRG neurones according to its molecular expression 
profile, revealing three distinct low-threshold mechanoreceptive neurones, two 
proprioceptive, and six principal types of thermosensitive, itch sensitive, type 
C low-threshold mechanosensitive and nociceptive neurones (Usoskin et al. 
2015) (Figure 1.2). Thakur et al have used a novel application of magnetic cell 
sorting (MAC) to isolate nociceptors and compared them to other DRG 
neuronal subtypes, and Chiu et al have used two mouse reporter lines to 
identify and purify a subset of DRG neurones in combination with IB4 surface 
labelling. Understanding the subgroups of DRG neurones is also being 
challenged by the differences in their in vitro and in vivo responses. In vivo 
GCaMP experiments suggest polymodality is an infrequent characteristic in 
vivo (Emery et al. 2016a). Discrepancies between conclusions of these 
methods may reflect the analysed sample (e.g. RNA vs protein), but also the 
impact of isolating DRG neurones from the surrounding tissues and mediators 
(e.g. pro-inflammatory, neurotrophic factors). 
 
 
Figure 1.2 Novel DRG classification proposed by Usoskin et al. 2015. 
This classification divides the DRG neurones into four main groups: neurofilament (NF), non-
peptidergic (NP), peptidergic (PEP) and tyrosine hydroxylase (TH). This new classification 
proposes new markers (top half of the table) with new novel additions in red. The bottom of 
the table refers to common markers already used in the field. (see abbreviation list page 11 
for further definitions) 
 
1.3 Nociceptor transduction 
The single unit of communication in the nervous system is an action potential. 
In contrast to the majority of central neurones, nociceptors do not normally 
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generate their action potentials at the axon of hillock but at peripheral nerve 
endings (Amir and Devor 1996, Amir and Devor 1997). Specific receptors at 
nociceptor’s nerve endings trigger nociceptive action potentials (Melzack and 
Wall 1965). These specific receptors are sensory transducers. They convert 
the energy of the stimulus (chemotransducers, thermoceptors or 




Figure 1.3 Voltage-gated Na+ and K+ conductances in action potentials. 
During an action potential (red line) there is an initial flow of sodium ions through voltage-gated 
ion channels (Na+ conductance) following by a repolarising conductance due to the flow of 
potassium ions (K+ conductance) (purple lines). (Taken from Kandel et al 2000) 
 
Action potentials are a result of flow of ions (conductance) through voltage-
gated ion channels. These are voltage-dependent Na+ currents, voltage-
dependent Ca2+ currents, voltage-activated K+ currents, calcium-activated K+ 
currents and the hyperpolarisation-activated current (Bean 2007). Described 
by Hodgkin and Huxley in the 50’s, these conductances occur in a defined 
sequence and shape an action potential (Figure 1.3) (Hodgkin and Huxley 
1952). Depolarisation of the membrane induces fast opening of Na+ channels 
(increase in Na+ conductance), inducing an inward Na+ current. This further 
discharges the neurone activating more Na+ channels, leading to an additional 
increase in Na+ conductance. This drives membrane potential up and causes 
the rising phase of the action potential. The rising phase is limited by the 
gradual inactivation of Na+ channels, reducing the positive inward current, and 
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the delay opening of K+ channels, creating an outward positive current that 
repolarises the membrane (repolarising phase, Figure 1.4). Other 
conductances such as Ca2+ also help to depolarise the neurone during the 
rising phase whereas Cl- conductance and hyperpolarisation-activated cation 
currents contribute to membrane repolarisation (Kandel et al. 2013). 
 
 
Figure 1.4 Different parameters of an elicited action potential. 
Action potentials may vary in width, upstroke, overshoot height, repolarising phase, 
afterhypopolarisation phase (AHP), and spike height. The initial current injected in the neurone 
must be sufficient to change the cell’s potential to reach the threshold (Vthresh) and produce a 
suprathreshold depolarising current (purple). Resting membrane potential (Vrest). (Adapted 
from Bean 2017) 
 
Sensory transducers have to generate a change in membrane potential that 
reaches the threshold to elicit an action potential. Evidence suggests 
nociceptor neurites have a resting membrane potential (Vrest) of -40 mV and at 
the soma between -50 and -75 mV (Baccaglini and Hogan 1983, Gold et al. 
1996). The threshold for action potentials of nociceptors in vitro is reported 
around -35 mV (Vthresh) (Gold et al. 1996). These are highly regulated events 
and in a disease state are known to be altered, resulting in abnormal firing and 
altered pain sensation (Matzner and Devor 1992).  
 
1.4 Voltage-gated sodium channels in DRG neurones  
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Changes in membrane potential alter the conformation of the VGSCs to open 
configuration which allows Na+ to flow. VGSCs are kinetically fast and have 
three basic conformations: open, closed and inactivated. The primary 
functional unit of VGSC is the a-subunit. It is the pore forming unit and it is 
sufficient for VGSC’s functional expression. The a-subunit of VGSCs has four 
similar repeated domains (I-IV) (Figure 1.5). S5-S6 transmembrane regions 
form the pore and S4 is involved in voltage sensing. When the membrane is 
at resting potentials, the VGSC is closed. Once the membrane is depolarised, 
the VGSC changes to an open conformation. When the neurone repolarises, 
inactivation occurs. This may be due to occlusion of the pore by intracellular 
loop between domains III and IV (fast inactivation) or the deactivation of the 
channel via closure of the pore (closed state). Thus, generating transient Na+ 
currents in DRG neurones (Cummins, Sheets and Waxman 2007). 
  
 
Figure 1.5 and table 1.1 VGSC secondary structure and a-subunit characteristics. 
Voltage-gated Sodium Channel (VGSCs) a-subunit has four repeated domains (I to IV), which 
are characterised by TTX, PKA, PKC interaction and the IFM inactivation. Different subtypes 
show different distribution within the nervous system and distinct TTX sensitivity. CNS, central 
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nervous system. DRG, dorsal root ganglion neurones. IFM, hydrophobic triplet motif. PKA, 
protein kinase A. PKC, protein kinase C. TTX, tetrodotoxin. (Taken from Lai et al. 2004) 
 
There are 9 a-subunits (Nav1.1-Nav1.9, and a putative tenth Nax) and 4 b-
subunits (Navb1-b4). a-subunits have specific developmental and cellular 
expression and may be associated with b-subunits which may stabilise, aid in 
localization or change the kinetics of the channel. DRG neurones show large 
variations in VGSC expression (see table 1.1).They may be separated by their 
tetrodotoxin (TTX) sensitivity and unique biophysical properties (Elliott and 
Elliott 1993, Namadurai et al. 2015, Lai and Jan 2006).  
 
1.4.1 TTX sensitivity 
DRG neurones are unique in their set of VGSCs, they express both TTX 
resistant (TTX-R) and TTX sensitive (TTX-S) VGSCs (Elliott and Elliott 
1993)(Table 1.1). TTX is a guanidinium compound more commonly known to 
be produced by bacteria in fish of the tetraodon genus such as the puffer fish 
(Moczydlowski 2013). It binds the pore of VGSCs and in a dose-dependent 
manner blocks the conductance of Na+, thus VGSCs affected at lower 
concentration are referred as sensitive and those affected at a higher dose are 
referred as resistant (Nav1.5, Nav1.8 and Nav1.9)(Chen and Chung 2014). 
 
1.4.2 Resurgent currents 
Resurgent currents result from an unusual form of gating that lead to the 
reopening of VGSCs during the repolarisation phase. In Purkinje cells, where 
they were first identified, resurgent currents lead to bursting activity (Raman 
and Bean 1997). This mechanism is thought to arise from an interaction with 
Navb4 and phosphorylation of the Nav1.6 channel. The cytoplasmic tail of 
Navb4 obstructs the pore and stops Na+ conductance (instead of the 
intracellular loop between domains III and IV of the a-subunit) and it blocks for 
a shorter time period than the normal inactivation (Grieco et al. 2005).  In DRG 
neurones, resurgent currents are seen in 40% of the large diameter neurones 
(Cummins et al. 2005).   
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1.4.3 Persistent currents  
Persistent currents were first identified in 1990 in hippocampal neurones 
(French et al. 1990). Persistent currents are Na+ conductance seen at resting 
membrane potentials, they are sensitive to TTX and very resistant to 
inactivation by depolarisation of the membrane. Thus, they are likely to play a 
role in the repetitive firing of action potentials (French et al. 1990). This 
alternative open state could result from G protein modulation or protein kinase 
phosphorylation of the a-subunit. The amplitude of persistent sodium currents 
in voltage-clamp experiments can reach 10% of the peak transient current. 
Nav1.6 has been associated with persistent currents in spinal sensory 
neurones (Cummins et al. 2005) and ataxia in mice (Meisler et al. 2002). In 
DRG neurones, Nav1.9 underlies a persistent TTX-R current in smaller 
neurones (Dib-Hajj et al. 1998, Tate et al. 1998, Dib-Hajj et al. 2002). 
Furthermore, lidocaine has been shown to supress ectopic firing while 
maintaining normal action potential firing (Devor, Wall and Catalan 1992). This 
is believed to be due to persistent current suppression by lidocaine (Dong et 
al. 2008).  
 
1.4.4 Action potential electrogenesis in DRG neurones 
As previously mentioned, action potentials are generated by changes in 
membrane potential and VGSCs play a crucial role in their formation. Evidence 
suggests that different a-subunits contribute to different parts of the action 
potential. Nav1.8 is considerate to contribute to the action potential overshoot 
and repetitive firing, Nav1.7 to the subthreshold activity and Nav1.9 to the 
modulation of the resting membrane potential (Figure 1.4) (Rush, Cummins 
and Waxman 2007). Furthermore, Nav1.8 has been described to be mostly 
expressed in damage sensing, nociceptor, neurones (Akopian et al. 1999, 
Kobayashi, Ohta and Terada 1993). However, VGSC expressions are not fixed 
and have been shown to change with painful pathologies (Tanaka et al. 1998, 
Okuse et al. 1997, Coggeshall, Tate and Carlton 2004, Villarreal et al. 2005, 
Strickland et al. 2008), and experimental procedures such as axotomy 
(increased expression of Nav1.3)  (Black et al. 1999). Nav1.3, Nav1.7, Nav1.8 
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Nav1.3 is a TTX-S channel with fast kinetics and recovery from inactivation. 
These are similar characteristics to Nav1.7, yet, Nav1.3 expression in DRG 
neurones is much lower. It is predominant in developing neurones, but 
downregulated in mature neurones (Beckh et al. 1989). Its levels increase 
during inflammation and following nerve injury (Waxman, Kocsis and Black 
1994, Kim et al. 2002, Black et al. 1999). Thus, there is a possible role in 
neuropathic pain. However, this role is controversial. Nav1.3 antisense 
administration intrathecally reduced chronic constriction injury’s pain 
phenotype (Hains et al. 2004), but no changes were seen in a spinal nerve 
injury model (Lindia et al. 2005) or in Nav1.3-null mice pain behaviour (Nassar 
et al. 2006). 
 
1.4.6 Nav1.7 
Nav1.7 was first identified in humans in 1997 (Sangameswaran et al. 1997). 
Transient currents obtained by Nav1.7 are TTX-S, exhibit rapid activation and 
inactivation, and slow repriming (recovery from inactivation) (Klugbauer et al. 
1995, Cummins, Howe and Waxman 1998). Thus, it is not considered to play 
a role in repetitive firing but in setting the threshold. Changes in the gating of 
Nav1.7 can induce painful pathologies such as inherited erythromelalgia and 
paroxysmal extreme pain disorder (Fertleman et al. 2006, McDonnell et al. 
2016). In contrast, loss-of-function mutations, but also hypofuntional are 
associated with congenital insensitivity to pain (Cox et al. 2006, Goldberg et 
al. 2007, Emery et al. 2015). Furthermore, Nav1.7 is upregulated in models of 
inflammatory pain (details reviewed in section 1.5) (Tanaka et al. 1998, Black 
et al. 2004), which is supported by Nav1.7 knock out studies and shRNA 
(Nassar et al. 2004, Yeomans et al. 2005). Hence, Nav1.7 selective 
antagonists are an attractive idea but studies have been met with complex 
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signalling that interacts with endogenous opioids (Emery, Luiz and Wood 
2016b, Isensee et al. 2017, Minett et al. 2015).  
 
1.4.7 Nav1.8 
Nav1.8 is resistant to TTX and contributes significantly to action potential 
electrogenesis in small DRG neurones (Renganathan, Cummins and Waxman 
2001). Due to the depolarised voltage-dependence of activation of the Nav1.8, 
they are considered to contribute to the overshooting of action potentials and 
repetitive firing (Renganathan et al. 2001). Recordings from Nav1.9 null mice 
have shown that typical TTX recordings are mediated by Nav1.8 (Akopian et 
al. 1999). In the context of inflammatory pain, PKA, calmodulin and contactin 
have been implicated in its modulation and likely to contribute to increased 
excitability of DRG neurones (details reviewed in section 1.5) (Gold et al. 1996, 
Zhang, Vasko and Nicol 2002). Nav1.8 is also unique in maintaining excitability 
at low temperatures. Nav1.8 knock out mice do not respond to noxious cold 
and noxious mechanical stimuli (Abrahamsen et al. 2008). 
 
1.4.8 Nav1.9 
Nav1.9 is also TTX resistant and preferentially expressed in small DRG 
neurones. It was first identified as the remaining TTX-R current in Nav1.8 
knock out mice (Cummins et al. 1999). It activates at potentials close to resting 
membrane potential (-60 mV to -70 mV), characterised by a steady-state 
inactivation curve, and also reported to produce persistent currents. Compared 
to other VGSCs a-subunits, Nav1.9 has very slow gating kinetics (Cummins et 
al. 1999). Multiple studies have demonstrated that Nav1.9 is heavily modulated 
(reviewed in section 1.5) (Baker et al. 2003, Coste et al. 2004, Rush and 
Waxman 2004). Since it is thought to contribute to threshold setting this can 




1.4.9 Expression and trafficking 
The expression profile of VGSCs in DRG neurones changes during 
development (Waxman et al. 1994, Benn et al. 2001). Once developed, small 
DRG neurones preferentially express three a-subunits: Nav1.7, Nav1.8 and 
Nav1.9 (Ho and O'Leary 2011). In the brain a-subunits are heavily 
glycosylated post-translation (Messner and Catterall 1985) and form an 
intracellular pool before joining the plasma membrane (Schmidt and Catterall 
1986) in a process of regulated exocytosis mediated by SNARE (N-
ethylmaleimide-sensitive factor attachment protein receptors) proteins 
(reviewed in section 1.6 and 1.7). In the process of regulated exocytosis, 
Nav1.7 has been shown to drive a positive feedback loop in Mat-LyLu prostate 
cancer cells via regulation of intracellular Na+ concentration interaction with 
adenylyl cyclase, which upregulates Nav1.7 trafficking to the plasma 
membrane (Brackenbury and Djamgoz 2007). Additionally, other proteins 
regulate their membrane insertion. For instance, the binding of annexin II light 
chain (p11) and PKA phosphorylation have been shown to aid the 
translocation to the plasma membrane of Nav1.8 (Assisted export, Figure 1.6) 




Figure 1.6 Multiple regulatory mechanisms for VGSCs expression.  
Summary of voltage-gated sodium channels (VGSCs) regulatory mechanisms that may 
regulate surface expression, such as, ER retention, surface retention, regulated endocytosis, 
regulated exocytosis and assisted export. ER, endoplasmic reticulum. NrCAM, neuronal cell 
adhesion molecule. (Taken from Cusdin (2008) 
 
Also regulating the expression at the plasma membrane are mechanisms for 
endocytosis and retention.  In adrenal chromaffin cells, an increase in 
intracellular Ca2+ during sustained activation increases levels of PKCa and 
calcineurin (Yanagita et al. 2000, Yanagita et al. 1996). This pathway and 
changes in intracellular Na+ concentration (Paillart et al. 1996) lead to 
endocytosis and subsequent lysosomal degradation (regulated endocytosis, 
Figure 1.6). Selective retention by specialised membrane proteins also 
interferes in VGSC regulation. For instance, contactin, a glycosyl-
phosphatidylinositol-anchored CAM protein expressed by neurones, 
associates with VGSCs and increases its functional expression (Kazarinova-
Noyes et al. 2001). 
 
The balance of the VGSCs is tightly regulated and its imbalance alters the 
excitability and pain sensation. Changes in VGSCs leads to 
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electrophysiological changes that lead to spontaneous and altered frequency 
of action potential firing. Increased Na+ conductance via increased VGSC 
expression at the plasma membrane may be sufficient to lower the threshold 
for action potential (Waxman et al. 1999). In inflammatory pain conditions, 
changes in pain sensation may be due changes in VGSCs expression induced 
by inflammatory mediators (Rush and Waxman 2004).  
 
1.5 Inflammatory pain  
Pain is a hallmark of inflammation. Tissue injury or infection lead to several 
inflammatory mediators to be released from damaged neurones, mast cells, t-
cells, epithelial cells, macrophages and neutrophils (Figure 1.7). These 
powerful inflammatory mediators such as ATP, bradykinin, PGE2, and 
serotonin are able to acutely change the excitability of DRG neurones (Ji and 
Strichartz 2004). Innocuous stimuli may be perceived as noxious (allodynia), 
responses to noxious stimuli may be exaggerated (hyperalgesia), and there is 
an increase in spontaneous firing leading to spontaneous pain (Meyer and 
Campbell 1981). These are a reflection of changes in ion channel and 
receptor’s function and expression at the plasma membrane which directly 




Figure 1.7 Inflammation elicits pain via inflammatory mediators and peripheral 
sensitization.  
In the event of inflammation, several inflammatory mediators are released at the site of injury 
from damaged neurones, mast cells, Schwann cells, satellite glia cells, epithelial cells, and 
infiltrating leukocytes. Powerful inflammatory mediators such as ATP, bradykinin, PGE2, and 
serotonin can acutely change the excitability of DRG neurones. (see abbreviation page 11 for 
further definitions) (Ji, Xu and Gao 2014) 
 
Peripheral sensitization results in increased pain sensation. In subject 
responses, hyperalgesia is characterised by decreased pain threshold, 
increased pain in response to suprathreshold stimuli and spontaneous pain 
(Meyer and Campbell 1981). In in vitro models these are characterised by a 
decrease in the threshold for action potential firing, increased firing to 
suprathreshold stimuli and spontaneous activity (Cummins et al. 2009). 
Inflammatory mediators may increase the response given to a specific 
stimulus, by increasing the current activated, or alter the ease with which 
action potentials are generated. Focusing on 7 major inflammatory mediators’ 
effects on DRG neurones – ATP, bradykinin, prostaglandin E2, histamine, 
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ATP is known to alter DRG excitability (Cook and McCleskey 2002, Li et al. 
1999). The concentration of ATP extracellularly is elevated following damage. 
Platelets and cell lysis are a rich source of extracellular ATP (Cook and 
McCleskey 2002).  Injection of ATP in human skin induces pain that is 
dependent on capsaicin-sensitive neurones (Hamilton et al. 2000). The 
nociceptors responsible for this response are likely to express P2X3 channels 
(Burnstock 2009). ATP directly activates nociceptors (Hamilton et al. 2000) 
and in vitro studies have demonstrated that cell damage directly activates 
inward currents in nearby nociceptors via ATP (Cook and McCleskey 2002). 
In addition, responses to ATP vary with soma size. Small diameter DRG 
neurones sensitive to capsaicin showed rapid-desensitizing ATP-activated 
currents whereas larger diameter insensitive to capsaicin had slower 
desensitizing ATP-activated currents (Li et al. 1999). In addition to P2X 
receptors, ATP may also activate P2Y receptors. These are G-protein coupled 
receptors (GPCRs) that are Gaq11-linked. CFA increases the expression of 
P2Y2 (Malin et al. 2008), a receptor that increases intracellular Ca2+ linked with 
increased DRG excitability (Malin and Molliver 2010, Yousuf et al. 2011).  
 
1.5.2 Bradykinin 
Bradykinin, a potent pain mediator, sensitizes nociceptors via B1 and B2, Gaq-
linked receptors (Steranka et al. 1988, Khan et al. 1992). B2 receptors are 
constitutively expressed in a variety of cells, including DRG neurones. 
Antagonists to this receptor have shown analgesic and anti-hyperalgesic 
properties in inflammatory models (Valenti et al. 2010, Cunha et al. 2007). In 
contrast, B1 receptors may be upregulated after tissue injury and potentiate 
currents elicited by TRPV1 activation (Vellani, Zachrisson and McNaughton 
2004). Addition of bradykinin to DRG cultures has been shown to depolarise 
DRG neurones (Jeftinija 1994, Rang and Ritchie 1988). A body evidence 
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supports this depolarisation is via PKC-e activation (Cesare et al. 1999). 
Excitatory effects of bradykinin are inhibited by PKC inhibitors and PKC 
activators depolarise DRG neurones by opening cation ion channels such as 
TRPV1 (Burgess et al. 1989, Premkumar and Ahern 2000, Vellani et al. 2001). 
However, TRPV1 knock out mice are susceptible to bradykinin effects 
(Katanosaka et al. 2008). Thus, bradykinin’s sensitization of TRPV1 alone 
does not explain nociceptor’s response. Furthermore, bradykinin has been 
shown to alter VGSC currents in DRG neurones. Bradykinin administration 
prolonged action potential length and inactivation is slowed, while activation 
was unaffected (Carratu and Mitolochieppa 1989). Possibly via PKA and PKC 
phosphorylation of the VGSCs. Bradykinin receptors are Gqa-linked and may 
induce the activation of these kinases.  
 
1.5.3 Prostaglandin E2 
Prostaglandin E2 (PGE2) is an eicosanoid. Although most eicosanoids do not 
act directly on nociceptors only enhance the sensation (Ballou et al. 2000), 10 
µM PGE2 has been found to up-regulate TTX-S sodium currents in capsaicin-
insensitive type-4 DRG neurones via activation of adenylyl cyclase and PKA 
(Tripathi et al. 2011), and 1 µM PGE2 to up-regulate TTX-R currents in 
neonatal DRG neurones via activation of adenylyl cyclase, PKA, and PKC 
(England, Bevan and Docherty 1996, Gold, Levine and Correa 1998). 
Furthermore, PGE2 increases excitability by reducing the threshold for 
activation of Nav1.8 and by increasing a hyperpolarisation-activated cyclic 
nucleotide-gated ion channel (HCN) current (Momin and McNaughton 2009, 
Gold et al. 1998). Thus, decreasing the time interval between action potentials. 
PGE2 administration has also been found to supress potassium outward 
currents, making the neurones more prone to action potential firing (Nicol, 
Vasko and Evans 1997). In addition to modulation of voltage-gated sodium 
channels, PGE2 modulates the activity of other channels such as 





Histamine is a widely distributed neurotransmitter that has four different types 
of receptors (H1-4). It has a major role in inflammation, nociception and 
pruritogenesis. In the CNS, activation of H1R (also Gaq11) enhances neuronal 
excitability and induces strong membrane depolarisation (Brown, Stevens and 
Haas 2001). For instance, bath application of 10 µM histamine depolarises 
cholinergic septal neurones by increasing TTX-R conductance, suggesting 
VGSC modulation (Gorelova and Reiner 1996). Knock out studies (histidine 
decarboxylase) have shown that histamine modulates acute pain in a dose-
response manner possibly due to an interaction with Nav1.8 (Yu et al. 2013). 
In DRG neurones, histamine potentiates the Bradykinin’s effects on 
nociception (Mizumura et al. 1995) and PGE2 sensitizes DRG neurones to 
histamine through cAMP-PKA pathway (Nicolson et al. 2007).  
 
1.5.5 Noradrenaline 
Noradrenaline is a key neurotransmitter and it is thought interact with DRG 
neurones via release from sympathetic nerve endings. It modulates pain 
through the binding of noradrenaline to a1A, a1B, a1D, and a2A adrenoceptors 
on DRG neurones (Maruo et al. 2006, Xie et al. 2001, Cheng et al. 2014). This 
excites DRG neurones and facilitates action potential firing (McLachlan et al. 
1993, Devor, Janig and Michaelis 1994, Xie et al. 1995). Yet, activation of a2 
in the absence of nerve injury may have an inhibitory effect on nociception 





During development NGF is a survival factor but in mature DRG neurones 
maintains the phenotype by being required for the continued expression of 
genes (Snider and McMahon 1998). NGF is increased during inflammation and 
it activates TrkA receptors present in IB4-negative neurones. Binding of NGF 
to TrkA activates three major signalling pathways: ERK (extracellular signal-
regulated kinase), PI3K (phosphatidylinositol-3-kinase) and phospholipase C 
gamma (PLC-g) (Kaplan and Miller 2000) which induce the upregulation of 
various ion channels, including Ca2+, K+(Park et al. 2003), and Na+. Both TTX-
S and TTX-R sodium currents are increased by NGF (Fjell et al. 1999a, Leffler 
et al. 2002, Okuse et al. 1997, Kerr et al. 2001, Gold et al. 1996, Zhang et al. 
2002). In NGF-induced hyperalgesia Nav1.8 is essential but not Nav1.9 (Kerr 
et al. 2001, Fjell et al. 1999b). Hence, increased TTX-R currents are likely due 
to Nav1.8 upregulation. In culture, NGF also increases TTX-R currents (Omri 
and Meiri 1990).  
 
1.5.7 Serotonin 
Serotonin (5-hydroxytryptamine, 5-HT) may be release by mast cells and 
platelets druing inflammation. DRG neurones have mRNA for 5-HT1B, 5-HT1D, 
5-HT2A, 5-HT2B, 5-HT3B, 5-HT4 and 5-HT7 receptors (Nicholson et al. 2003, 
Amaya-Castellanos et al. 2011). Receptor expression is distinct between DRG 
subpopulations. For example, 5-HT3 agonists directly activate c-fiber 
nociceptors (Moalem, Grafe and Tracey 2005). Their expression is increased 
in inflammation and 5-HT3 antagonists reduce pain induced by serotonin 
injection (Sufka, Schomburg and Giordano 1992). Serotonin has been shown 
to modulate hyperpolarisation-activated cation current in type-4 DRG 
neurones (capsaisin insensitive). It binds 5-HT7 receptors which increase 
cAMP levels, shifting the voltage dependency of hyperpolarisation-activated 
cation currents and increasing excitability (Cardenas et al. 1999). In type-2 
DRG neurones (capsaicin sensitive), serotonin reduced the threshold for 
action potential firing possibly via modulation of TTX-R sodium current 
(Cardenas, Cardenas and Scroggs 2001). Furthermore, it has been described 
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that the activation of 5-HT2C increases neuronal excitability and mediates 
sensitisation of TRPV1 (Salzer et al. 2016).  
 
1.4.8 VGSC trafficking in inflammatory pain 
Taken together, the effects of the described inflammatory mediators highly 
modulate PKA, cAMP, and PKC which are known to regulate the expression 
of VGSCs (Figure 1.6 & 1.7). Single knock out studies for Nav1.7, Nav1.8, and 
Nav1.9 have shown the importance of these channels in inflammatory 
conditions (Nassar et al. 2004, Maingret et al. 2008, Amaya et al. 2006, 
Akopian et al. 1999, Abrahamsen et al. 2008) and changes in their expression 
are seen in different models of inflammatory pain. Tanaka and colleagues have 
reported in a carrageenan model of inflammation an increase in Nav1.8 mRNA 
and TTX-R current (Tanaka et al. 1998). The authors suggest a role for NGF 
as increased NGF levels have been detected following carrageenan injection 
(Woolf et al. 1994) and NGF upregulates Nav1.8 gene expression in vitro 
(DibHajj et al. 1996). However, Okuse and colleagues demonstrated in a 
carefully controlled RNAse experiments that Nav1.8 mRNA changes in a NGF-
induced hyperalgesia model do not underlie protein expression changes. 
Instead these changes occur at the level of post-translation and post-
transcription (Okuse et al. 1997). In other inflammation models such as CFA, 
the TTX-R Nav1.8 was also found to be upregulated (Coggeshall et al. 2004). 
Using a PGE2-induced inflammatory model, the importance of Nav1.8 
increased transcription was further supported in both acute and chronic 
inflammatory pain (Villarreal et al. 2005). In addition to TTX-R current increase, 
Nav1.7 expression and TTX-S current has also been demonstrated to increase 
in a carrageenan model (Black et al. 2004). Hence, although different 
inflammatory insults were used Nav1.7 and Nav1.8 seem to consistently 
upregulate in inflammation. To further understand, the mechanism behind the 
upregulation of Nav1.7 and Nav1.8, Gould and colleagues pre-treated the 
animals with ibuprofen (a cyclooxygenase 2 inhibitor and thus interferes PGE2 
synthesis) before injecting with CFA. The pre-incubation with ibuprofen 
prevented the Nav1.7 and Nav1.8 up-regulation and links the cyclooxygenase 
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pathway to the upregulation of these channels during inflammation (Gould et 
al. 2004). 
 
1.7 SNARE proteins 
Neurotransmitter release and ion channel upregulation during inflammation 
are a consequence of vesicular trafficking and membrane fusion (Black et al. 
1999, Tanaka et al. 1998, Garry and Hargreaves 1992, Karanth et al. 1991, 
Kilo et al. 1997, Meng et al. 2016). Membrane fusion is a hallmark of eukaryotic 
cells. It provides the ability to segregate biochemical reactions within 
compartments, such as the endoplasmic reticulum, and to communicate 
between organelles through the exchange of vesicles (Figure 1.8). Organelles 
such as the endoplasmic reticulum contain proteins that define their functions 
but also transient proteins on the way to other parts of the cell (biosynthetic 
transport). A new vesicle is formed from a membrane-bound organelle, the 
donor, and the cargo loaded to be delivered to the acceptor organelle (Bock et 
al. 2001). SNARE proteins are the primary mediators of this process, and they 
regulate multiple trafficking pathways (Martens and McMahon 2008). 
Exocytosis is the best-studied event of membrane fusion. It is the fusion of a 
vesicle with the plasma membrane to release its contents such as 
neurotransmitters (Borisovska et al. 2005). 
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Figure 1.8 The assignment of SNAREs to intracellular membrane-trafficking pathways.  
VAMP isoforms, also R-SNAREs, are depicted in blue. Specific VAMP isoforms are thought 
to combine with other specific Q-SNAREs to perform fusion events within the biosynthetic 
transport pathway (Taken from Jahn and Scheller 2006). 
 
The human SNARE superfamily has 36 members localised in different 
intracellular compartments (Figure 1.8), and members are characterised by 
the presence of one or two SNARE motifs (a unique 60 - 70 amino acid 
sequence). Originally, SNARE proteins were subdivided as t-SNAREs, those 
present at the ‘target’, the acceptor membrane, and v-SNARES, for ‘vesicular’, 
and present in vesicles. However, multiple SNAREs can be found in both the 
vesicles or the target. Hence, another classification subdivides them as Q-
SNARES or R-SNARES and it is based on the presence of arginine and 
glutamine residues in the SNARE motif (Figure 1.8)(Fasshauer et al. 1998). 
Q-SNARES are further subdivided in Qa-, Qb-, Qc- and Qbc-SNAREs 
according to their similarity to syntaxin and SNAP25 (both members of the Q-
SNARE subdivision) (Hong 2005, Bock et al. 2001).  
 
The role of SNARE proteins in membrane fusion was first revealed from a 
crystal structure of a neuronal SNARE complex. The crystal exhibited four 
SNARE motifs: two SNARE motifs from SNAP25, one from syntaxin 1A and 
another from VAMP (Vesicle-associated membrane protein) (Sutton et al. 
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1998).  One mechanistic model of vesicle fusion to the plasma membrane 
supports that 4 SNARE motifs are required to come together in a four-helix 
bundle (trans-SNARE complex, Figure 1.9). This trans-SNARE complex is 
composed of Qa-, Qb-, and Qc- SNAREs and R-SNAREs. Thus, one member 
of each class is necessary to form a SNARE complex (QabcR). These 
complexes are energetically favourable and drive docking and fusion of the 
vesicle with the membrane (Figure 1.9) (Jahn and Scheller 2006). Different 
combinations of Qa/Qb/Qc/R-SNAREs form at different steps intracellularly 
(Figure 1.8). However, some complexes, which do not contain one member of 
each class, such as Qaaaa or QbccR have been shown to fuse in artificial 
systems (Yang et al. 1999, Feldmann et al. 2009). It is possible that these non-
viable complexes in biological systems are formed to inhibit the formation of 
other SNARE complexes (Feldmann et al. 2009). 
 
 
Figure 1.9 The SNARE conformational cycle during vesicle docking and fusion.  
SNARE complexes assemble at the acceptor membrane first as “loose” complexes (bottom 
left). Regulatory proteins aid the in the fusion process, resulting in “cis”-SNARE complexes 
and complete membrane fusion (middle right). NSF and a-SNAP bind and form disassembly 
complexes which are then removed in an energy consuming reaction. SM proteins rearrange 
Trans-SNARE complexes spatially and temporally. NSF, N-ethylmaleimide-sensitive factor. 
SNARE, N-ethylmaleimide-sensitive factor attachment protein receptor. (Taken from Jahn and 
Scheller 2006)  
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Controlling the trans-SNARE complexes are complexins and SM proteins. 
Complexins associate with tight trans-SNARE complexes, acting as a clamp 
to fusion until the appropriate Ca2+ signal arises. Once the specific transient 
intracellular Ca2+ increase occurs, it triggers vesicle fusion by activating Ca2+ 
sensitive synaptotagmin which reverses the action of complexin and thus 
allowing fusion to be completed. SM proteins organise the trans-SNARE 
complex spatially and temporally. There are seven SM proteins: Munc18-1, 
Munc18-2, Munc18-3, VPS33A, VPS33B and SLY1 (Hong and Lev 2014). SM 
proteins may regulate the formation of acceptor t-SNARE dimers composed of 
syntaxin and SNAP-25 as well as contribute to the final fusion step through an 
as of yet undefined mechanism (Sudhof and Rothman 2009). Once membrane 
fusion has occurred the cis-SNARE complexes are unzippered and recycled 
by the N-ethylmaleimide-sensitive factor (NSF) and soluble NSF attachment 
proteins (SNAPs) (Jahn and Scheller 2006). 
 
SNARE proteins may reside predominantly in one subcellular compartment 
and participate in specific intracellular fusion steps but this is not the case for 
all SNARES (Hong 2005). SNARE proteins cannot be the only determinants 
of specificity as they are present in both anterograde and retrograde vesicles. 
Additional specificity is provided by accessory and regulatory proteins such as 
Sec1p, Munc-18, synaptotagmins, Rab, GTPases and their effectors which 
vary across cell types and trafficking pathways (Bonifacino and Glick 2004).  
 
1.7.1 VAMPs 
VAMP proteins are a subgroup of the SNARE family composed of 7 isoforms: 
VAMP1 and 2 (also synaptobrevin 1 and 2), VAMP3 (cellubrevin), VAMP4, 
VAMP5 (myobrevin), VAMP7 (tetanus sensitive-VAMP, TI-VAMP) and VAMP8 
(Jahn and Scheller 2006). VAMP proteins are anchored to the vesicular 
membrane through the C-terminal transmembrane domain (Baumert et al. 
1989) (Figure 1.10). In contrast to VAMP1/2/3/5 and 8, VAMP4 and VAMP7 
have additional N-terminus extensions. VAMP4 contains a di-leucine motif and 
acidic clusters corresponding to the recycling from the endosome to the trans-
Golgi network (TGN) (Zeng et al. 2003) and VAMP7 has a longin domain 
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involved in both the endocytic and the secretory pathway (Schafer et al. 2012). 
This is reflected on their molecular size (Table 1.2). Each VAMP isoform has 
shown differences in tissue distribution and fusion events, which are described 
below. 
 
Figure 1.10 Domain organization of the SNAREs discussed in this thesis.  
SNAP25, soluble N-ethylmaleimide-sensitive attachment protein 25. SNARE, N-
ethylmaleimide-sensitive factor attachment protein receptors. TM, transmembrane.   VAMP, 
vesicle-associated membrane protein. (Adapted from Hong and Lev, 2014) 
 
 
Table 1.2 The molecular size of the VAMP isoforms.  




VAMP1 was the first VAMP isoform described. It was isolated from synaptic 
vesicles hence it is also known as synaptobrevin 1 (Trimble, Cowan and 
Scheller 1988, Baumert et al. 1989). VAMP1 knockout mice show severe 
neurologic defects and die by postnatal day 15 (Nystuen et al. 2007). In 
VAMP1-heterozygous mice there is loss of Ca2+ sensitivity at the 
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neuromuscular junction due to the absence of VAMP1. Thus, VAMP1 is 
essential and non-redundant in Ca2+ triggered exocytosis at the 
neuromuscular junction (Liu, Sugiura and Lin 2011). VAMP1 has been 
detected in CNS, pancreas, kidney, cardiac myocytes and in trigeminal ganglia 
(Rossetto et al. 1996, Ferlito et al. 2010, Meng et al. 2007). It is thought that 
VAMP1 also mediates regulated exocytosis in non-neuronal tissues. In mouse 
trigeminal ganglia neurones, VAMP1 mediates the CGRP release elicited by 
bradykinin and high K+ (60 mM) in vitro (Meng et al. 2007). 
 
1.7.1.2 VAMP2  
VAMP2, or synaptobrevin 2, was also originally isolated from synaptic vesicles 
(Trimble et al. 1988, Baumert et al. 1989). It has an essential role in Ca2+ 
triggered neurotransmitter release. VAMP2-null mice have shown 100-fold 
decrease of evoked synaptic exocytosis and die at postnatal day zero (Schoch 
et al. 2001). In central synapses, VAMP2 is the predominant v-SNARE 
interacting with the plasma membrane SNAREs, SNAP25 and syntaxin 1, to 
promote exocytosis (Sudhof and Rothman 2009). VAMP2 has also been 
detected in non-neuronal tissues such as the kidney (Procino et al. 2008), lung 
(Wang et al. 2012), pancreas (Regazzi et al. 1995), stomach (Karvar et al. 
2002), adipocytes (Martin et al. 1998) and skeletal muscle (Rose et al. 2009), 
where it also profiles in regulated exocytosis (Mendez et al. 2011, Wang et al. 
2012, Regazzi et al. 1995), transport of aquaporin 2 (Procino et al. 2008), and 
glucose transporter 4 (Rose et al. 2009).   
 
1.7.1.3 VAMP3 
VAMP3, or cellubrevin, is ubiquitously expressed and it has been associated 
with sorting/early and recycling endosomes (McMahon et al. 1993). Yet, 
deletion of VAMP3 gene in mice exhibits little effects on development or 
physiological processes, suggesting functional redundancy (Pryor et al. 2004, 
Antonin et al. 2000a). For instance, VAMP2 and VAMP3 are capable of 
substituting each other to a varying degree in exocytosis in chromaffin cells 




VAMP4 is predominantly localised in the trans-golgi network and 
early/recycling endosomes (Peden, Park and Scheller 2001, Mallard et al. 
2002). However, a recent study has placed VAMP4-enriched vesicles in the 
hippocampus as the key participants in asynchronous neurotransmitter 
release. So, in contrast to VAMP2, which is involved in rapid Ca2+-dependent 
synchronous release, VAMP4 does not readily interact with complexins and 
synaptotagmin 1, which are required for the fast Ca2+-dependent release 
(Raingo et al. 2012). 
 
1.7.1.5 VAMP5 
Originally cloned as muscle-specific isoform, VAMP5, or myobrevin, has been 
shown unable to drive vesicular fusion with the plasma membrane’s t-
SNAREs, syntaxin1/SNAP-25 and syntaxin5/SNAP25 (Hasan, Corbin and Hu 
2010). It is not found in the CNS but it is expressed in skeletal and cardiac 
muscle cells where it is mainly associated with the plasma membrane and 
intracellular vesicles (Zeng et al. 2003). 
 
1.7.1.6 VAMP7 
VAMP7, or tetanus neurotoxin insensitive VAMP (TI-VAMP), was first 
identified in epithelial cells due to its insensitivity to tetanus neurotoxin (section 
1.8) (Galli et al. 1998). Further studies have described VAMP7 in the vesicular 
transport between endosomes and lysosomes (Advani et al. 1999), trans-Golgi 
network (Chaineau, Danglot and Galli 2009), but it has also been correlated 
with synaptic vesicle fusion. Bal and colleagues (2013) have demonstrated 
that in presynaptic hippocampal neurones, the glycoprotein reelin, an 
endogeneous neuromodulator, selectively mobilizes vesicles containing 
VAMP7 (but not VAMP2, VAMP4 or vti1a) independent of electrical activity. In 
addition, VAMP7 is essential in vesicular mediated neurite outgrowth in 
staurosporine-differentiated PC12 cells (Martinez-Arca et al. 2000). In 
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neuronal cultures, VAMP7 has been associated with neurite outgrowth when 
cultures are coated with laminin (Gupton and Gertler 2010). 
 
1.7.1.7 VAMP8 
VAMP8, or endobrevin, is believed to mediate fusion of early and late 
endosomes. It is ubiquitously expressed and enriched in epithelial cells in the 
lung, pancreas, intestine and kidney (Wong et al. 1998). In pancreatic acinar 
cells, VAMP8 null mutations have shown that VAMP8 is the major v-SNARE 
of zymogen granules and thus enzymatic secretion (Wang et al. 2004). 
 
1.8 Botulinum neurotoxins and chimaeras 
Botulinum neurotoxins (BoNT) are extremely potent toxins produced by 
clostridium bacteria to cause muscle paralysis and death. They are subdivided 
in an enzymatic domain (light chain) and a binding domain (heavy chain) 
(Figure 1.11 A). All seven serotypes (A, B, C, D, E, F and G) interact with 
vesicle fusion machinery but all have different modes of action which  reflect 
the duration of the paralysis they cause (Davletov, Bajohrs and Binz 2005). 
BoNT/A (commercial name BOTOX) cleaves the SNARE protein SNAP25 and 
is already used for a number of disorders arising from hyper activity of 
autonomic or motor neurones. Importantly, in a clinical trial with chronic 
migraine sufferers the administration of BOTOX significantly reduced the 
number of migraine attacks (Dolly and O'Connell 2012). Other serotypes such 
as BoNT/B, BoNT/D, BoNT/F and BoNT/G are known to cleave VAMP1, 
VAMP2 and VAMP3 (see Appendix 4 for cleave sites) (Foran et al. 2003, 
Schiavo et al. 1992, Yamasaki et al. 1994). Hence, BoNTs are powerful tool in 
understanding the function of SNARE proteins in cellular physiology. 
 
Tetanus toxins (TeNT) have similar structural features to BoNTs. It also has 
an enzymatic and binding domain. However, TeNTs bind at the presynaptic 
membrane of the neuromuscular junction and it is transported to the spinal 
cord whereas BoNTs intoxicate the neuromuscular junction. The enzymatic 
domain of TeNTs cleave VAMP2 (Montecucco, Schiavo and Rossetto 1996). 
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1.8.1 Mechanism of action 
Botulinum and tetanus neurotoxins bind gangliosides found at the plasma 
membrane (PM) to gain entry to the intracellular medium (Figure 1.11 B). 
Different BoNT serotypes and TeNT are thought to use different gangliosides: 
Synaptotagmin is used by BoNT/B and BoNT/G; synaptic vesicle protein 2 is 
used by BoNT/A/D/E/F; and glycosylphosphatidylinositol(GPI)-anchored 
proteins is used by TeNT (Blum et al. 2014). Once bound to the ganglioside 
the neurotoxin is endocytosed and the acidity of the endosome leads to the 
cleavage and reduction of the neurotoxin (Figure 1.11 B ii and A). 
Consequently, the separated enzymatic domain, the light chain, can then 
cleave the target SNARE as described above and impair neurotransmission 
(Davletov et al. 2005).  
 
 
Figure 1.11 Mechanism of action of botulinum neurotoxins.  
(A) Botulinum neurotoxins (BoNTs) have their disulphide bonds cleaved and reduced once 
they gain entry in the cell, and thus separating the enzymatic domain (light chain). (B) BoNTs 
gain entry intracellularly by binding gangliosides (via heavy chain) at the plasma membrane. 
During endocytosis (i) the BoNTs are taken in by the cells, low pH (ii) causes the separation 
of the light chain, which is then freed to cleave its target (iii). (Taken from Davletov 2005). 
 
1.8.2 Tetbot A and tetbot B 
Tetbot A and tetbot B are chimaeras of the botulinum and tetanus neurotoxins 
(Designed by the Davletov group, University of Sheffield). They both have the 
binding domain of TeNTs but differ in the enzymatic domain, tetbot A has 
BoNT/A, and tetbot B has BoNT/B. Hence, tetbot A cleaves SNAP25 (Ferrari 
et al. 2013) and tetbot B cleaves VAMP1/2/3. In rats, intrathecal pre-injection 
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of tetbot A has been shown to reduce the effects of CFA hindpaw injection by 
significantly reducing mechanical hypersensitivity (Ferrari et al. 2013). 
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1.8 Aim and objectives 
During inflammatory pain, the release of inflammatory mediators alters the 
function of nociceptors (section 1.5). Nociceptors show increased 
neurotransmitter release, hyperexcitability and changes in the expression of 
ion channels. Although it is possible that other processes are involved in the 
regulation of ion channels’ expression at the plasma membrane (section 
1.4.9), this thesis aimed to explore the role of SNARE proteins in the 
excitability induced by inflammatory mediators. 
 
Objectives: 
•    to establish an in vitro inflammation model 
•    to investigate the effects of combined inflammatory mediators on VGSC 
trafficking 
•    to identify the VAMP isoforms expressed in DRG neurones 
•    to explore the potential of the engineered toxins, tetbot A and tetbot B, to 






2 – Materials and methods 
 
2.1 Animals  
C57/BL6 male mice were used in this project were from a house colony. The 
initial breeding pairs were purchased from Charles River (U.K.) and these were 
regularly replaced to avoid inbreeding. For immunocytochemistry and western 
blotting experiments mice were 8-14 weeks old whereas for patch clamp 
experiments mice were 6-8 weeks old. This difference is due optimisation of 
patch clamp recordings. More recordings were possible when younger animals 
were used. All animals were culled by cervical dislocation in accordance with 
the Animals (Scientific Procedures) Act 1986 Amendment Regulations 2012. 
 
2.2 Plate and coverslip coating 
2.2.1 Matrigel 
Matrigel basement membrane matrix aliquots (BD, 356231) were defrosted at 
4ºC for at least 2 h. Borosilicate glass coverslips (thickness 1.5, VWR) washed 
in 70% ethanol and autoclaved were added to 12 or 24 well plates and placed 
in the fridge to cool. Once the matrigel aliquot defrosted, it was diluted with 
sterile distilled water (25 μl/mL) and layered onto coverslips using ice-cold 
autoclaved pipette tips. The excess was removed by tipping the plate. The 
coated coverslips were then incubated for 20-30 min at 37ºC.  
 
2.2.2 Poly-L-lysine 
Borosilicate glass coverslips (thickness 1.5, VWR) were washed in 70% 
ethanol and autoclaved. Poly-L-lysine hydrobromide (Sigma-Aldrich) was 
prepared in sterile distilled water (100 μg/mL) and applied to the coverslips (or 
plate when generating lysates for western blot). The coverslips were 
subsequently incubated for 30min at room temperature and washed three 
times with phosphate-buffered saline (PBS, Sigma-Aldrich). The coverslips 




Laminin (Gibco) at 20μg/mL was added to poly-L-lysine coated coverslips and 
incubated for 1-2 h. The laminin excess was removed after incubation by 
washing the coverslips three times with sterile distilled water just before plating 
the cells. 
 
2.3 DRG isolation and culturing 
2.3.1 Cell preparation for Immunocytochemistry 
(Chapter 2) 
Dorsal root ganglia neurones were removed from mice and put in ice-cold 
PBS. After removing the connective tissue the ganglia were put into an enzyme 
solution containing 0.588 mg/ml collagenase XI (2U/mg), 0.98 mg/mL Dispase 
II (0.84U/mg), 155 mM sodium cloride, 4.8 mM sodium hepes, 5.6 mM hepes, 
1.5 mM dipotassium phosphate and 10 mM glucose (all Sigma-Aldrich) at 
pH7.3 37ºC 5% CO2 for one hour. The neurones were then dissociated by 
triturating up and down with a 1000 μL pipette and spun down 134 g in a 15% 
Bovine albumin solution (Sigma-Aldrich). The pellet was resuspended in 5 mL 
culture medium [Dulbecco’s modified Eagle’s medium F12 with glutamax (Life 
technologies), 10% foetal bovine serum (Life technologies) and 1% 
penicillin/streptomycin (Gibco)] and spun down 134 g. The matrigel-coated 
coverslips were prepared and the isolated neurones (from the pellet) were 
added. After one hour, the wells were flooded with more culture medium (12 
well plate 1 mL per well). Details about the duration of DRG culture (24h or 
48h) are referred in the results section as it varies between experimental sets. 
 
2.3.2 Cell preparation for immunocytochemistry 
(Chapter 1 and 3), patch clamp and western blot  
Dorsal root ganglia neurones were removed and put in ice cold PBS. Once 
dissection was completed the supernatant was removed and the ganglia 
resuspended in medium [Dulbecco’s modified Eagle’s medium F12 with 
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glutamax (Life technologies), 10% foetal bovine serum (Life technologies), 1% 
penicillin/streptomycin (Gibco), 47 mM glucose (Sigma)] containing 500 µg/ml 
collagenase (Sigma). After incubating for 30 min at 37ºC the collagenase 
solution was removed and replaced with 0.25mg/ml trypsin-EDTA (Sigma) and 
incubated again for further 30min at 37ºC. Once the trypsin-EDTA digestion 
finished the neurones were washed by adding 9 mL of medium  and 
centrifuged for 1 min  134 g twice. To isolate the neurones within the ganglia 
the pellet was resuspended in 2 mL and triturated with a 19G needle (5 times) 
and 23G needle (3 times).  The isolated DRG neurones were then washed by 
adding 8 mL of medium and spun down for 3 min 134 g. The isolated neurones 
(pellet) were resuspended in medium and added to poly-L-lysine/laminin 
coated coverslips with cloning cylinders (Sigma-Aldrich). 
 
2.3.3 In vitro inflammatory model 
In this project I have used an inflammatory soup to produce an in vitro model 
of inflammation. This soup consisted of 2 µM ATP disodium salt hydrate 
(dissolved in dH2O), 50 nM bradykinin acetate salt (dissolved in 0.1 M acetic 
acid), 500 nM prostaglandin E (dissolved in dH2O), 1 µM histamine 
dihydrochloride (dissolved in dH2O), 500 nM (-)-noradrenaline (dissolved in 0.5 
M HCl), 50 ng/mL nerve growth factor β from rat (dissolved in 0.1% bovine 
serum albumin) and 1 µM serotonin hydrochloride (dissolved in dH2O) all 
compounds from Sigma-Aldrich. This selection is based on previous published 
experiments by Maingret et al 2008. The appropriate solvent controls were 
performed side by side. All ingredients were mixed together in a master stock 
and frozen at -20ºC until use except for serotonin, which was made up fresh 




After 24-48h in culture medium the neurones were washed with PBS and fixed 
for 10 min at room temperature with 4% paraformaldehyde 4% sucrose in PBS. 
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Followed by permeabilization for 10 min with 0.1% Triton X100 (for intracellular 
epitopes), blocking for 2 h with 0.2% fish skin gelatin 0.02% Triton X100 (the 
latter for intracellular epitopes), and by exposure to the primary antibodies for 
16 h. After the primary antibody incubation, the wells containing the coverslips 
were washed 3 times (each 15min incubation) with the blocking solution.  The 
secondary antibodies were added afterwards and incubated for further 2 h at 
room temperature wrapped in foil. The unbound secondary antibodies were 
washed out with PBS with 3 incubations 15 min each. Just before mounting 
slides were cleaned with 70% ethanol solution and a drop of mounting media 
was added (southern biochem). Lastly, the coverslips were dipped in distilled 
water and carefully placed on top of each mounting media drop. The coverslips 
were then secured with nail varnish. 
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VAMP1 Polyclonal Rabbit Synaptic 
Systems 
1:500 1:1000 
VAMP2 Polyclonal Rabbit Synaptic 
Systems 
1:500 1:2500 
VAMP3 Polyclonal Rabbit Synaptic 
Systems 
1:500 1:1000 
VAMP4 Polyclonal Rabbit Andrew 
Peden’s lab 
1:500 1:1000 
VAMP5 Polyclonal Rabbit Synaptic 
Systems 
1:100 1:2000 
VAMP7 Polyclonal Rabbit Andrew 
Peden’s lab 
1:100 1:500 
VAMP8 Polyclonal Rabbit Andrew 
Peden’s lab 
1:100 1:1000 
β-III tubulin	 Monoclonal Mouse R&D systems 1:1000 1:1000 
Nav1.7 
(intracellular) 
Monoclonal Mouse Neuromab 1:1000 N/A 
Nav1.7 
(extracellular) 
Polyclonal Rabbit Alomone  1:1000 1:200 
Nav1.8 Polyclonal Rabbit Alomone 1:500 1:200 
Nav1.9 Polyclonal Rabbit Alomone 1:500 1:200 
Navb4 Polyclonal Rabbit Alomone 1:500 1:800 
VR1 Polyclonal Goat Santa Cruz 1:100 N/A 















N/A Goat Life 
Technologies 
1:1000 N/A 





2.4.2 Image deconvolution 
High resolution deconvolved images were generated using a Deltavision RT 
system (Applied Precision, Issaquah, Washington). Images were collected 
using a 60x oil immersive objective 1.4 N.A., a Photometrics CoolSnap HQ2 
CCD camera and the software SoftWorx. The landweber algorithm was used 
to deconvolve the images. 
 
2.4.3 Confocal microscopy 
Confocal line-scanning was performed using a Nikon A1 confocal system 
(Tokyo, Japan) with an oil immersive objective 60x 1.4 N.A.. Images were 
acquired with a resolution of 0.20 µm per pixel.  
 
2.4.4 InCell analyser 
The slides were imaged using an “InCell analyser 2200” (GE Healthcare, USA) 
and single cell analysis using “Developer’s toolbox” (GE healthcare, USA). The 
average diameter of each soma was measured using the β-III tubulin staining 
when DAPI staining was present (Figure 2.1). DRG neurones were counted 
positive for the expression of VAMP proteins if the intensity of the staining was 
higher than 90% of the background intensity of no primary antibody control 
coverslips. 
        
Figure 2.1 Single cell analysis.  
(A) Raw image. (B) Image depicting a representative measurement of somata diameter. Using 
 “InCell analyser 2200” software (GE Healthcare, USA) DRG neurones’ average diameter was 
automatically measured (yellow line) according to b-III tubulin staining (red). This example 
depicts one DRG neurone (left) with a diameter of 10 µm and 5 µm (right). 
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2.5 Electrophysiology recordings 
2.5.1 Patch clamp set up 
DRG neurones platted on coverslips were placed on a perfusion chamber on 
the stage of an inverted microscope (Zeiss Axiovert 100). This chamber was 
fed by a perfusion system driven by gravity and balanced by an outflow 
generated by pump made vacuum. Electrophysiology recordings were 
acquired using an EPC10-USB amplifier (HEKA Elektronik, Germany) with 
PatchMaster software (HEKA software, version 2.65, Germany).  
 
DRG neurones were chosen according to their binding properties to Isolectin 
B4 (IB4-FITC). Before each recording coverslips were incubated with 6µg/ml 
IB4-FITC (Sigma Aldrich) diluted in standard recording solution for 10 min at 
room temperature (20-22ºC). DRG neurones negative to IB4 were identified 
using a 488 nm wavelength generated by a monochromator (Polychrome IV 
unit TILL Photonics LPS-150) and imaged with a 512B CCD camera (Roper 
Scientific, Photometrics UK). Metamorph® (Meta Imaging) software was used 
to acquire transmitted and emitted light of each DRG neurone recorded (Figure 
2.2).      
 
Figure 2.2 Patch-clamp set up, TBDmCherry and IB4-FITC.  
(Brightfield) Brightfield representative image of dorsal root ganglia (DRG) neurone with a 
pipette tip on the left. (TBDmCherry) Tetanus binding domain conjugated with mCherry 
discriminate non-IB4 positive DRG neurones (Chapter 5, section 5.2.1).  (IB4-FITC) FITC 
signal of the same field. The DRG neurone depicted in the image with the recording pipette 




2.5.2 Patch pipettes 
Pipettes used for patch clamp recordings were filamented thin-wall galss 
capillaries (World precision instruments) pulled with a vertical gravity driven 
puller (Narishige model PC-10, Japan) to achieve a cone shape and resistance 
of 3.5 - 4.5 MΩ when filled with internal solution. 
 
Patch pipettes were coated with Sylgard® (Dow corning) to reduce pipette 
capacitance transients during recordings. Sylgard® solution was prepared in 
advance by mixing 9 parts resin to with 1 part catalyst oil, mixing well and 
aliquoting in -20ºC until use. The Sylgard® solution was added to the shank of 
pulled pipettes and heat cured with a fine heating coil. 
 
To increase the chances of a GΩ seal during recordings the sylgarded pipette 
tips were also fire-polished using a heat filament (Narishige microforge M-83, 
Japan). 
 
2.5.3 Whole-cell configuration 
Patch pipettes filled with internal solution were lowered into the bath while a 
200 ms 5 mV voltage step at 5 Hz was applied to monitor pipette resistance. 
Positive pressure was applied to the patch pipettes to prevent any debri from 
blocking the tip. Once close to the soma, the positive pressure was released 
and gentle negative pressure was applied to form a GΩ seal between the 
pipette tip and the DRG neurone (cell-attached mode). A holding potential of -
60 mV was set and pipette capacitance was compensated using the C-fast 
control. To achieve whole-cell mode, further suction was applied until the 
membrane at the tip of the pipette was removed and the DRG cell capacitance 
transients were observed. These were compensated using the C-slow control. 
 
2.5.4 Recording solutions 
Standard recording solution contained (in mM): 45 NaCl, 2 KCl, 5 NaHCO3, 10 
C8H18N2O4S (HEPES), 10 C6H12O6 (glucose), 2.5 CaCl2 and 1 MgCl2 adjusted 
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to pH 7.3 with NaOH and to 310 mOsm with C12H22O11 (sucrose). For voltage 
clamp experiments the VGSC currents were isolated using (in mM): 45 NaCl, 
3 KCl, 20 (C2H5)4N(Cl) (tretaethylammonium chloride), 75 C5H14ClNO (choline 
chloride), 0.1 CdCl2, 10 HEPES, 1 MgCl2, 1 CaCl2, 10 glucose adjusted to 
pH7.3 with NaOH and with 300 mOsm adjusted with sucrose. For zero sodium 
solutions used in voltage clamp 45 mM NaCl was replaced with 45 mM choline 
chloride. 
 
 The internal solution used for current clamp experiments contained (in mM): 
130 KCl, 10 [-CH2OCH2CH2N(CH2CO2H)2]2 (EGTA), 10 HEPES, 8 NaCl, 1 
CaCl2, 4 Mg2ATP, adjusted to pH7.3 with NaOH and 300 mOSm with sucrose. 
The internal solution for voltage clamp experiments contained (in mM): 20 
NaCl, 130 CsMeSO4, 10 HEPES, 0.2 EGTA, 0.3 NaGTP, 4 Mg2ATP adjusted 
to pH7.3 with CsOH and osmolarity 300-308 mOsm with sucrose.  Internal 
solutions were filtered (pore size 0.2 µm) before added inside the pipettes. 
 
2.5.5 Liquid junction potential  
Liquid junction potentials in patch clamp recordings occur when the filled patch 
pipette enters the bath, this due to the different composition of the internal and 
the bath solutions. Thus, it is dependent on the diffusion coefficients of the 
solutions’ components, which in turn are dependent on ionic charge and 
concentration. The liquid junction potential of each internal and recording 
solution combination can be measured experimentally (Neher 1992). Briefly, 
by setting the amplifier in current clamp mode with zero current injection and 
using a 3 M KCl filled pipette as ground electrode when both solutions are then 
put in contact (first same in the pipette and bath to zero) a voltage difference 
may be recorded. This is the liquid junction potential. For my experiments, the 
junction potential measured was 3 mV. Liquid junction potential is not present 
in whole-cell mode as the recordings were made after the pipette solution has 






2.5.6 Series resistance  
The series resistance (Rs) is the sum of all resistances between the amplifier 
input and the cell membrane. The current flowing through the circuit goes 
through the resistance across the pipette (Rp) and the cell membrane (Rm) 
(Figure 2.3) and this can create two recording errors: voltage drop and 
reduction of the temporal resolution.  
 
The voltage drop occurs when the series resistance decreases the amount of 
current flowing through the circuit and thus the voltage at which the cell is being 
clamped is not the one desired. If the series resistance is compensated the 
amplifier adjusts its input according to the calculated series resistance. 
Likewise, the series resistance affects the temporal resolution, as the access 
time constant is equal to Cm times Rs.  
 
                                                   
Figure 2.3 A simplified circuit schematic of the patch clamp amplifier.  
(amp) amplifier, (Rs) series resistor, (Rm) cell membrane resistor, (Cm) cell membrane 
capacitance. 
 
When series resistance could not be lowered physically (debris on the pipette 
tip) it was compensated electronically using Rs comp control. Ideally, the series 
resistance would be compensated 100% but due to a positive feedback 
circuitry this may lead to oscillation and cell death. In my experiments, series 






2.5.7 Data analysis 
Data analysis was performed using the built in online analysis of PatchMaster 
software (Heka Eletronik). Graphs were generated with IgorPro (version 6) and 
GraphPad Prism (version 6.0d). 
 
2.5.7.1 Action potential analysis 
Action potentials acquired in current clamp mode were analysed using the 
action potential analysis function built in from Fitmaster. The parameters are 
described in the figure below. 
 
 
Figure 2.4 Parameters used in the analysis of action potentials. 
Image adapted from Fitmaster manual reference 2.90 by Heka Elektronik. AHP, 
afterhyperpolarisation. 
 
Other parameters not included in the figure: 
- Amplitude – peak of the action potential (in blue) to trough of the action 
potential (in green) 





2.6 Western blot 
2.6.1 Lysate preparation 
DRG lysates were prepared straight after dissection or after being cultured for 
24-72h. When prepared after dissection, the DRG ganglia were washed in 
PBS and immersed in complete lysis buffer (RIPA, Sigma-Aldrich, with 
protease inhibitor II at 0.05%, Fisher Scientific). When collecting DRG from 
DRG culture, the neurones were washed twice with cold PBS before adding 
the complete lysis buffer, and scrapped off with a cell scrapper. This cell 
suspension was then homogenized using a motor pestle (VWR) for 
approximately 1min at 4ºC and placed on a horizontal rotator for 1 h at 4ºC. 
The lysed DRG neurones were then spun down for 15 min at 4ºC 15,279 g 
and the supernatant removed and aliquoted until needed -20ºC. 
 
2.6.2 Protein content quantification 
To determine the protein content of the DRG lysates, the DC protein assay kit 
II (Biorad) was used. The manufactor’s instructions were followed. Briefly, a 
bovine albumin serum standard curve and triplicate sample dilutions were 
added to a 96 well plate, topped up with a protein detecting agent and 
incubated for 2 h at 37ºC. Absorbance was measured at 565 nm using a 
microplate reader, Expert Plus Microplate reader (Biochrom Ltd). The 
absorbance values generated were then used to determine the protein 
concentration of the samples. 
 
2.6.3 Loading sample preparation 
Loading samples were prepared using a 4X lamelli buffer (Bio-Rad 
laboratories) and made up at 1:1 ratio. These were boiled at 95ºC (VAMP 
proteins) or 55ºC (VGSC proteins) for 5 min and gently spun down to remove 
any precipitate. An equal amount of protein was loaded per lane and pre-
stained ladder makers were loaded alongside to identify the size of the protein 
bands (Fisher scientific 26616 and 26619). To detect changes in protein 
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amount between samples, the loading concentrations used were below the 
saturating range of the imaging system (Figure 2.5). 
 
                           
            
Figure 2.5 Determination of the maximum protein loading.  
(Top) Fluorescent image of a western blot imaged with the LiCor system depicting increasing 
concentrations of DRG lysate. Leftmost lane is the protein size ladder in KDa. Rightmost lane 
lists the antibodies used. (Bottom) Signal intensity of each band according to the amount of 
protein loaded. 
 
2.6.4 Protein electrophoresis 
Handcast gels were prepared according to the size of the proteins of interest 
and included a running (7.5% or 15%) and stacking (4%) segment (Table 2.2). 
The handcast gels were placed in the mini-PROTEAN® electrophoresis 
system (Bio-Rad laboratories), submerged in running buffer (25 mM 















trisaminomethane, 0.2 M glycine and 13.4 mM sodium dodecyl sulfate in 





 4% 7.5% 15% 
Acrylamide 30% 13.5 % 23% 50% 
1.5 M Tris-HCl pH8.8 23.5% 28.8% 25% 
10% SDS 0.9% 1.15% 1% 
dH20 61.2% 69% 22.9% 
10% APS 0.6% 0.3% 1% 
TEMED 0.3 % 0.1% 0.1% 
Table 2.2 Contents of the gels used for protein electrophoresis.  




2.6.5 Protein blotting 
The protein-containing gels were transferred onto a wet transfer system, Mini 
Trans-Blot® cell (Bio-Rad laboratories), with either a nitrocellulose membrane 
(pore size 0.2 µm) [GE Healthcare, U.S.A.] or for detection of VAMP3 immune-
Blot® PVDF membrane (Bio-Rad laboratories). The electrophoretic transfer 
was induced by a 100 mV for 1 h (VAMPs) or 20 mV overnight at 4ºC (VGSCs) 
while submerged in transfer buffer (25 mM trisaminomethane, 0.2 M glycine 
and 20% methanol in dH2O).  
 
2.6.6 Blocking and antibody incubations 
All membranes were blocked against unspecific binding at room temperature 
(20-23ºC) for 1 h with 5% semi-skimmed milk – TBST (20 mM Tris, 137 mM 
NaCl and 0.1% TWEEN® 20 pH7.4 with HCl – all Sigma-Aldrich) except for 
experiments detecting VAMP3 where 5% semi-skimmed milk – PBST (PBS 
with 0.1% TWEEN® 20 pH7.4) was used instead. 
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Once the membranes were blocked for 1 h the primary antibodies were added 
(see Table 2.1 for details). GAPDH (1:2000 ThermoFisher, USA) and β-III 
tubulin (1:1000 R&D systems) were used as loading controls and to identify 
the neuronal content of the samples. All primary antibody incubations were 
done overnight at 4ºC on a roller and diluted in TBST (PBST for VAMP3). 
 
To remove unbound primary antibodies the membranes were washed 3 times 
with TBST before the secondary antibodies were added (goat anti-mouse IgG 
(H+L) secondary antibody DyLight 680 conjugate and goat anti-rabbit IgG 
(H+L) secondary antibody DyLight 800 [Thermofisher Scientific] both at 
1:5000) and incubated at room temperature for 1 h. Which was followed by 3 
further washing steps to remove excess secondary antibody. 
 
2.6.7 Membrane imaging and analysis 
Once the membrane dried completely it was imaged, analysed and annotated 
using the Li-Cor odyssey CLx imaging system with Image Studio Lite software 
(Li-Cor Biosciences Ltd, U.K.). Protein bands were analysed by drawing a box 
of a set size to measure median intensity in all bands.  
 
2.7 ELISA 
DRG calcitonin-gene related peptide (CGRP) was measured using a 
commercial kit by Phoenix Pharmaceuticals, Inc (USA). This is a competitive 
enzyme immunoassay with 100% specificity for mouse CGRP within 0 – 100 
ng/mL. Experiments were performed as per manufacturer’s instructions and 
plate readings were taken with iMark Ô microplate absorbance reader at 450 




Mouse DRG cultures were cultured for 72 h using standard medium 
(experiments performed by Drs Seward, Bauer and Nassar). Total RNA was 
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extracted and processed in collaboration with Paul Heath (Sheffield Institute 
for Neuroscience). The microarray chip used was an Agilent SurePrint G3 
Gene Expression 8X60K. Dr Marta Milo performed the statistical analysis. 
Probability of positive log-ratio (PPLR) was calculated due to the low n 
numbers used. This method uses a Baesian hierarchical model to calculate 
upregulated and/or downregulated genes rather than p values. In this thesis 
only the control group values are presented.  
 
2.9 Other reagents used 
Name Source Concentration 
Tetbot A Davletov lab 10 nM (dissolved in 
0.4% n-octylglucoside) 
Tebot B Davletov lab 













300 nM (dissolved in 
H2O) 
Table 2.3 List of other reagents used.   
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3 – The effects of an inflammatory 




In the event of inflammation, several inflammatory mediators are released at 
the site of injury from damaged neurones, mast cells, Schwann cells, satellite 
glia cells, epithelial cells, and infiltrating leukocytes. Powerful inflammatory 
mediators such as ATP, bradykinin, PGE2, and serotonin can acutely change 
the excitability of DRG neurones (Ji and Strichartz 2004), causing innocuous 
stimuli to be perceived as noxious (allodynia), responses to noxious stimuli to 
be exaggerated (hyperalgesia), and an increase in spontaneous firing leading 
to spontaneous pain (Meyer and Campbell 1981). These are a reflection of 
changes in ion channel function and expression at the plasma membrane 
which directly influence many aspects of DRG excitability.  
 
Voltage-gated sodium channels (VGSCs) are located in the plasma membrane 
and play a fundamental role in the generation of action potentials. Altered 
VGSC expression has a profound effect on the excitability of nociceptors (Lai 
et al. 2004). Numerous studies have shown increased expression of VGSCs 
in different models of inflammatory pain. For instance, there is evidence for 
Nav1.8’s upregulation in a carrageenan (Tanaka et al. 1998), NGF (Okuse et 
al. 1997), CFA (Coggeshall et al. 2004), PGE2 (Villarreal et al. 2005) 
inflammatory pain models, and in a model of chronic inflammatory joint pain 
(Strickland et al. 2008). Thus, VGSCs altered expression during inflammation 
poses a captivating target in the prevention of hypersensitivity and possibly the 
chronicity of pain. Here, I aim to further understand the effects of combined 
inflammatory mediators on VGSC trafficking by establishing an in vitro 





3.2.1 Inflammatory soup induces hyperexcitability in 
DRG neurones. 
In order to establish an in vitro inflammation model, a selection of inflammatory 
mediators (2 µM ATP, 50 nM bradykinin, 500 nM prostaglandin E, 1 µM 
histamine, 500 nM noradrenaline, 50 ng/mL NGF and 1 µM serotonin) based 
on previous published experiments by Maingret et al 2008 were added to 
isolated DRG neurones 1-2 h after isolation (Figure 3.1) (more details on 
inflammatory soup see section 2.3.3). The DRG neurones were treated for 22h 
and before each recording, coverslips were incubated with IB4-FITC for 10 min 
at 6 µg/mL. As I am primarily interested in nociceptors, in this study, I chose to 
restrict investigations to only small (definition section 1.2.5) IB4-negative DRG 
neurones (mostly peptidergic). Furthermore, by only using IB4-negative 
neurones together with size as selection criteria, I hoped to avoid 
misinterpreting changes in ion channel function induced by inflammation with 
differences arising from different neuronal subpopulations. All recordings from 
DRG neurones included in the analysis had a stable (3 min) resting membrane 
potential more negative than – 45 mV before applying the protocol and action 
potential amplitude crossing the 0 mV threshold. All the recordings were 
paired: one mouse culture was used for the control (solvent control) and the 




Figure 3.1 The inflammatory soup induces hyperexcitability in DRG neurones. 
Isolated DRG neurones were incubated with the inflammatory soup (IS) for 22h, added to the 
medium 1h after flooding the culture. (A) Representative traces of current clamp recordings at 
twice rheobase of DRG neurones after 22 h incubation (right) and control (left). (B) Frequency 
of action potentials at rheobase and twice rheobase (2x, as indicated on the bar), (C) current 
threshold for action potential, (D) resting membrane potential, and (E) soma diameter. Error 
bars show SEM except (B) where median with interquartile range is plotted (non-parametric 
data set). Each data point corresponds to a DRG neuron. In total data from 7 mice are 
represented. **p<0.01 kruskal-wallis test *p=0.0214 Mann-Whitney test (nControl=18, nIS=15, 
N=7) 
 
The hallmarks of hyperexcitability in neurones correspond to a decreased 
current threshold and increased firing frequency in response to suprathreshold 
stimulation (Cummins et al. 2009). Thus, to understand the effects of IS on 
DRG excitability a series of sequentially increasing current steps were applied 
to determine the action potential rheobase for each DRG neurone of matched 
treated and untreated cultures. The frequency of action potentials was 
quantified at rheobase and twice rheobase (suprathreshold stimuli). Under 


































































action potential frequency (Figure 3.1 B, Kruskal-Wallis test p=0.0003, multi 
comparisons p<0.01) and a significant reduction in threshold (Figure 3.1 C, 
Mann-Whitney test p=0.0214). The control DRG neurones had a median of 2 
Hz frequency at both rheobase and twice rheobase in contrast to IS treated 
DRG neurones with a median of 2 Hz at rheobase and 8 Hz at twice rheobase. 
The threshold median for the untreated DRG neurones was 115 compared 
with 40 pA for treated neurones (nControl=18, nIS=15, N=7). These findings are 
not due to changes in the resting membrane potential of the neurones (Figure 
3.1 D) or differences in size of the DRG neurones recorded (Figure 3.1 E). The 
resting membrane potential of control DRG neurones was -63 ± 8 mV and for 
the IS treated -64 ± 11 mV. The soma diameter of the DRG neurones selected 
for recording in each group was on average 25 ± 6 µm for the control group, 
and 21 ± 4 µm for the IS treated group. The results of Maingret et al. 2008 had 
shown increased excitability after 3 min incubation, and these results after 22 
h of the addition of the inflammatory mediators further confirm the 
hyperexcitability in DRG neurones induced by IS incubation but are likely not 
due to the same mechanisms. 
 
3.2.2 Inflammatory soup does not significantly alter 
action potential properties but alters timing of the first 
action potential at twice rheobase. 
To further investigate the effects of IS on the action potential’s 
electrophysiological properties, key measurements were taken from the first 
action potential of both treated and untreated group at rheobase and twice 
rheobase (Figure 3.2, nControl=18, nIS=15, N=7, detailed information on how the 
measurements were taken can be found in the methods’ section 2.5.7.1). The 
threshold for action potential firing remained unchanged in all four groups of 
action potentials measured (Figure 3.2 A, control rheobase: -48 ± 7 mV, control 
twice rheobase: -40 ± 7 mV, IS rheobase: -46 ± 9 mV, IS twice rheobase: -41 
± 9 mV). The threshold is thought to be regulated by the activity of Nav1.7 and 
Nav1.9, and possibly Nav1.3 (Rush et al. 2007).  Similarly, no significant 
changes were seen in amplitude where Nav1.8 activity is the major contributor 
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(Figure 3.2 B, control rheobase: 73 ± 28 mV, control twice rheobase: 69 ± 22 
mV, IS rheobase: 76 ± 23 mV, IS twice rheobase: 77 ± 14 mV). The 
afterhyperpolarisation of neurones, mostly a combination of Na+ channels’ 
inactivation and K+ conductance, also had no significant changes (Figure 3.2 
C, control rheobase: 73 ± 11 mV, control twice rheobase: 70 ± 9 mV, IS 
rheobase: 66 ± 15 mV, IS twice rheobase: 70 ± 11 mV). The integral, which is 
an indication of net ionic current as function of voltage (Figure 3.2 D, control 
rheobase: 47 ± 36 µV, control twice rheobase: 34 ± 18 µV, IS rheobase: 43 ± 
41 µV, IS twice rheobase: 33 ± 16 µV), and the action potential overshoot, 
contributed mainly by Nav1.8 (Figure 3.2 D, control rheobase: 36 ± 9 mV, 
control twice rheobase: 35 ± 12. mV, IS rheobase: 34 ± 9 mV, IS twice 
rheobase: 35 ± 8 mV) showed no significant differences with the pre-incubation 
of the IS. Furthermore, the duration of the action potential showed no 
differences between groups (Figure 3.2 F, control rheobase: 2± 0.6 ms, control 
twice rheobase: 2 ± 0.6 ms, IS rheobase: 2 ± 0.6 ms, IS twice rheobase: 2 ± 
0.9 ms). Hence, these results suggest that neither the function nor the 
expression of these channels was altered in this in vitro model. Significant 
changes were only seen at the interval duration between the start of the 
stimulus and the peak of the action potential (Figure 3.2 G, control rheobase: 
18 ± 15 ms, control twice rheobase: 4 ± 3 ms, IS rheobase: 33 ± 24 ms, IS 
twice rheobase: 8 ± 3 ms). This was significantly decreased with the IS 
incubation at twice rheobase compared to rheobase (p=0.02, one-way ANOVA 
with Brown-Forsythe post hoc test). 
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Figure 3.2 Inflammatory soup does not significantly alter action potential properties 
but alters timing of the first action potential at twice rheobase. 
Isolated DRG neurones were incubated with the inflammatory soup (IS) for 22h. Only the first 
action potential of the rheobase (1x) or twice rheobase (2x) was analysed. (A) Threshold 
(ANOVA p=0.0304 but lost after post hoc analysis), (B) amplitude, (C) hyperpolarisation, and 
(D) integral of the action potential from the first to the second threshold crossing, relative to 
the threshold amplitude. (E) Overshoot and (F) duration of the action potential. (G) The time 
between protocol initiation and action potential amplitude maximum. Error bars show SEM. 
Each data point corresponds to a DRG neuron from seven mice. *p=0.02 one way ANOVA 
with Brown-Forsythe post hoc test (nControl=18, nIS=15, N=7) 
 
  








































































































3.2.3 Inflammatory soup induces hyperexcitability in 
DRG neurones after 6h incubation 
Thus far, the IS soup was added to the DRG neurones’ medium for 22h. This 
time point was chosen to further understand the impact of VGSC trafficking. 
To maximise the time between DRG culture and experiments, a time course 
of the effects of the IS incubation on DRG excitability was performed (Figure 
3.3). The earliest the IS was added was one hour after plating, and for 22 h, 6 
h and 2 h before patch clamp recordings were acquired (Figure 3.3 A). 
Hyperexcitability was seen only from 6 h (control rheobase: 2 ± 2 Hz, control 
twice rheobase: 2 ± 10 Hz; IS 6 h rheobase: 2 ± 5 Hz, IS 6 h twice rheobase: 
16 ± 26 Hz p<0.05) and at 22 h (rheobase: 2 ± 6 Hz, twice rheobase: 8 ± 10 
Hz, p<0.05 Kruskal-Wallis test, nControl=15, n2h=5, n6h=5, n22h=12, N=6). Similar 
to previous results (Figure 3.1 C), the threshold for action potential firing seems 
to decrease with the addition of IS. Data acquired in this set of experiments 
are not significantly different (Median for control: 100 pA, IS 2 h: 90 pA, IS 6 h: 
50 pA and IS 22 h: 40 pA; Kruskal-Wallis test p=0.1075), revealing a degree 
of variability between the data sets. The resting membrane potential of the 
DRG neurones recorded was also not altered by the IS incubation at any of 
the time points measured (Figure 3.3. D; control: -62.93 ± 6.5 mV, IS 2 h: -65 





Figure 3.3 Inflammatory soup induces hyperexcitability after 6 h incubation.  
(A) Isolated DRG neurones were incubated with the inflammatory soup (IS) for 2h, 6h and 
22h. (B) Frequency of action potentials at rheobase and twice rheobase, (C) current threshold 
and (D) resting membrane potential. Error bars show SEM except (B) where median with 
interquartile range is plotted. Each data point corresponds to a DRG neuron from six mice. 
The control set is composed of DRG neurones recorded at 2, 6 and 22 hours, which were 
found not be significantly different (data not shown). *p<0.05 kruskal-wallis test (nControl=15, 
n2h=5, n6h=5, n22h=12, N=6). 
 
3.2.4 Inflammatory soup (6 h) increases TTX-R sodium 
currents  
Inflammatory mediators have been previously described to increase both TTX-
resistant (TTX-R) and -sensitive (TTX-S) currents (Gold et al. 1996, Black et 
al. 2004, Maingret et al. 2008). After establishing that the IS affects DRG 
neurones’ excitability at 6 h, I aimed to confirm if the observations of increased 
TTX-R and TTX-S sodium currents could be seen after a 6 h incubation with 
the IS. Voltage-clamp recordings were established, and the neurones were 
held at -70 mV. Increasing steps in voltage (-60 mV to 60 mV) were applied to 
record VGSC current flowing through voltage-gated sodium channels. To 
isolate VGSC currents, 20 mM tetraethylammonium chloride (blocks voltage-
gated K+ channels) and 0.1 mM cadmium chloride (blocks voltage-gated Ca2+ 
channels) were used in the extracellular solution. Three hundred nanomolar 
TTX was used to separate Nav1.1/Nav1.3/Nav1.7 (TTX-S) and Nav1.8 & 
Nav1.9 (TTX-R). No IS was perfused during the recordings.  
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Representative traces of voltage clamp recordings of DRG neurones of the 
similar cell capacitance depict an increase in TTX-R currents in DRG neurones 
treated with IS (Figure 3.4 A). I/V analysis of normalised current to cell body 
capacitance shows a significant increase in TTX-R current in IS treated DRG 
neurones (Figure 3.4 B). Average peak current increased from -40.21 pA/pF 
to -149.3 pA/pF. Total VGSC current also showed increased peak current in 
IS treated DRG neurones but did not reach significance (control: -117.4 pA/pF 
IS: -209 pA/pF). No significant changes were seen in TTX-S peak current 
(control: -105.6 pA/pF IS: -69.51 pA/pF; two-way ANOVA, nvehicle=9, nIS=8, 
N=6). Increased TTX-R peak current likely contributes to the increased 
excitability associated with IS (Figure 3.1 and Figure 3.3). Nav1.9, a TTX-R 
channel, is known to contribute to persistent sodium currents and the traces 
suggest a component of persistent current as the inactivation slope appears 
slower in treated cells (Figure 3.4 A).  
 
Figure 3.4 Inflammatory soup increases TTX-R sodium current in DRG neurones. 
Isolated DRG neurones were incubated with the inflammatory soup (IS) for 6h. (A) 
Representative traces of total VGSC current and the subtracted TTX sensitive and TTX 
resistant sodium current. (B) Respective I/V curves normalised to cell size (pA/pF). Error bars 
show SEM. TTXR sodium current is significantly different between control and IS. Two-way 
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3.2.5 Does Inflammatory soup (6 h) induce trafficking 
of VGSC to the plasma membrane? 
Evidence suggests that VGSCs are heavily regulated after an inflammatory 
insult through phosphorylation or changes in plasma membrane expression 
(Black et al. 1999, Tanaka et al. 1998, Devor et al. 1989, England et al. 1994, 
Khasar, Gold and Levine 1998). In this inflammation model, the inflammatory 
mediators induce hyperexcitability in DRG neurones after 6 h (Figure 3.3). It 
remains unknown the mechanism underlying these effects if it is due to 
trafficking of VGSCs, channel modulation and/or changes in other biophysical 
properties of the DRG neurones (e.g. voltage-gated calcium 
channels)(Zamponi et al. 2015). Hence, to explore the idea of changes in 
VGSC trafficking, isolated DRG neurones were fixed after being incubated for 
6 h with IS. Antibodies against Nav1.7, Nav1.8, Nav1.9 and Navb4 were 
incubated in combination with IB4 (all targeting extracellular epitopes except 
Nav1.9) (Figure 3.5). These antibodies were also tested in rat cortical 








Figure 3.5 Representative images of VGSC Nav1.7, Nav1.8, Nav1.9 and subunit Navb4 
expression at the plasma membrane of DRG neurones’ soma. 
Isolated DRG neurones were cultured for 24 h and incubated with and without inflammatory 
soup for 6 h before fixing with paraformaldehyde. Immunocytochemistry was performed to 
identify expression of VGSC Nav1.7, Nav1.8, Nav1.9 and subunit Navb4 (in red) close to the 
plasma membrane of treated and untreated neurones. DRG neurones were also probed for 
IB4 (green) to identify the peptidergic population (IB4 negative) and DAPI (blue) to identify the 
nuclei. Images were acquired using a confocal microscope. Scale bar shows 20 µm. 
 
VGSC Nav1.7, Nav1.8, Nav1.9 and the subunit Navb4 were observed at the 
plasma membrane of both IB4 positive and negative DRG neurones (Figure 
3.5). Representative images for each a-subunit and Navb4 were taken with a 
confocal microscope at the level of the soma to assess changes in expression 
(to match electrophysiology recordings from the soma). Surprisingly and in 
contrast to what was indicated by the voltage clamp experiments (section 3.2.1 
& 3.2.4), higher staining intensity was observed for Nav1.7 and Nav1.9 in 
control conditions than treated with IS. A total of 560 somas were analysed 
using ImageJ (nNav1.7=169 NNav1.7=3, nNav1.8=154 NNav1.8=4, nNav1.9=164 
NNav1.9=3 and nNavb4=73 NNavb4=2). Each soma was analysed by hand drawing 
a band around the plasma membrane (delimited with the aid of the contrast 
function and IB4 staining) and measuring the integrated density of the signal. 
Surprisingly, it strongly suggests a decrease in expression of VGSC Nav1.7 
and Nav1.9 at the plasma membrane of DRG neurones following 6 h 




Figure 3.6 Quantification of VGSC Nav1.7, Nav1.8, Nav1.9 and subunit Navb4 
expression at the plasma membrane of DRG neurones’ soma. 
Isolated DRG neurones were cultured for 24 h and incubated with inflammatory soup for 6 h 
before fixing with paraformaldehyde. Immunocytochemistry was performed to identify 
expression of Nav1.7, Nav1.8, Nav1.9 and Navb4 at the plasma membrane of treated and 
untreated neurones with inflammatory soup. Images were acquired using a confocal 
microscope. Integrated density was calculated using ImageJ and JaCOP plug in. Mean values 
are plotted and error bars show SEM (nNav1.7=169 NNav1.7=3, nNav1.8=154 NNav1.8=4, nNav1.9=164 
NNav1.9=3 and nNavb4=73 NNavb4=2).  *p=0.0207 **p=0.0043 unpaired t-test 
 
Furthermore, VGSC expression was also quantified according to IB4 binding 
to non-peptidergic DRG neurones (Stucky and Lewin 1999) (Figure 3.7). 
Changes in expression of Nav1.8 and Navb4 within IB4 negative and IB4 
positive DRG neurones remained unchanged. In contrast, Nav1.7 expression 
decreased significantly in IB4 negative neurones only (p=0.0451 n=82 one-
way ANOVA with Tukey’s multiple comparison test) and Nav1.9 on both IB4 
negative and positive (p<0.01 nIB4positive=75 nIB4negative=89 one-way ANOVA 
with Tukey’s multiple comparison test). Measurements were selected after 
using robust regression and outlier removal (ROUT) method (Graph Pad Prism 



































































Figure 3.7 Quantification of VGSC Nav1.7, Nav1.8, Nav1.9 and subunit Navb4 
expression at the plasma membrane of IB4 positive and negative DRG neurones. 
Isolated DRG neurones were cultured for 24 h and incubated with inflammatory soup for 6 h 
before fixing with paraformaldehyde. Immunocytochemistry was performed to identify 
expression of Nav1.7, Nav1.8, Nav1.9 and Navb4 at the plasma membrane of treated and 
untreated neurones with inflammatory soup. DRG neurones were also probed for IB4 to 
identify the peptidergic population (IB4 negative). Images were acquired using a confocal 
microscope. Integrated density was calculated using ImageJ and JaCOP plug in. Mean values 
are plotted and error bars show SEM (IB4 negative nNav1.7=82, nNav1.8=87, nNav1.9=89 and 
nNavb4=39, IB4 positive nNav1.7=87, nNav1.8=67, nNav1.9=73 and nNavb4=34).  *p=0.0451 ***p<0.01 
One-way ANOVA with Tukey’s multiple comparison test. 
 
Because these results were not in agreement with those in voltage clamp 
experiments, DRG neurones were also stained for TRPV1 (Figure 3.8 A). 
TRPV1 is a non-selective cation channel gated by noxious heat, protons and 
capsaicin previously reported to be upregulated in a CFA model of 
inflammation (Amaya et al. 2003). Intriguingly, the expression of TRPV1 close 
to the plasma membrane (intracellular epitope) was also significantly 
decreased in both IB4 negative and positive neurones (Figure 3.8 B) (p<0.001 
nIB4positive=54 nIB4negative=66 one-way ANOVA). Previously reported increase in 
TRPV1 expression was observed in histochemical slices of intact dorsal root 


































































reproduce this effect in vitro. Hence, it raises the possibility that changes might 
be happening at the level of the neurites.  
 
 
Figure 3.8 TRPV1 expression at the plasma membrane of IB4 positive and negative 
DRG neurones decreases after treatment with inflammatory soup. 
Isolated DRG neurones were cultured for 24 h and incubated with inflammatory soup for 6 h 
before fixing with paraformaldehyde. Immunocytochemistry was performed to identify 
expression of TRPV1(red) close to the plasma membrane of treated and untreated neurones 
with inflammatory soup. DRG neurones were also probed for IB4 (green) to identify the 
peptidergic population (IB4 negative) and DAPI (blue) to identify nuclei. (A) Representative 
images of TRPV1 expression. Images were acquired using a confocal microscope. Scale bar 
shows 20 µm. (B) Quantification analysis of TRPV1’s expression in IB4 positive and negative 
DRG neurones. Integrated density was calculated using ImageJ and JaCOP plug in. Mean 
values are plotted and error bars show SEM (IB4 negative n=66, IB4 positive n=54, N=2).  
**p=0.00489 ****p<0.0001 One-way ANOVA 
 
3.2.6 Inflammatory soup incubation (6 h) does not alter 
VGSC protein expression of Nav1.7  
To further understand the effects of the inflammatory soup incubation on 
Nav1.7 and Nav1.9 expression in DRG neurones, DRG cultures treated and 
untreated with IS were lysed and their proteins separated by electrophoresis 
(Figure 3.9 A). The rationale behind these experiments was to evaluate the 
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impact of the IS on Nav1.7 and Nav1.9 protein expression given the 
contradictory results of the immunocytochemistry data, which suggest a 
downregulation of the channel.  Due to technical issues, the Nav1.9 signal 
could not be detected. Thus, only Nav1.7 was quantified over 3 different 
cultures from 3 different mice (Figure 3.9 B). Nav1.7 protein bands were 
normalised to the respective b-III tubulin band. Statistical analysis, paired t-
test, showed no significant difference between the lysates. Thus, it suggests 




Figure 3.9 Quantification of VGSC Nav1.7 expression in isolated DRG neurones 
treated and untreated with inflammatory soup. 
(A) Representative immunoblot depicting Nav1.7 expression (~200 kDa) and b-III tubulin. This 
particular immunoblot was also probed for Navb4 subunit hence the band at ~30 kDa. (B) 
Quantification of 3 separate immunoblots of 3 different mice cultures treated and untreated 
with inflammatory soup (IS). The median intensity of Nav1.7 was normalised to the b-III tubulin 
loading control. Data not significantly different paired t-test. Error bars show SEM. 
 
3.3 Discussion 
The main goal of this chapter was to establish an in vitro model of inflammation 
that would induce hyperexcitability and could subsequently be used to test the 
role of SNARE proteins and toxins targeting these proteins in pain. The IS 
induced hyperexcitability from 6 h, decreasing the threshold for firing and 
increasing the frequency of action potentials. Further characterisation of the 
effects of the IS showed a significant increase in TTX-R Na+ current, 
suggesting modulation and/or changes in the expression of Nav1.8 and 



































the expression of Nav1.7 and Nav1.9 at the soma plasma membrane. 
Changes in the density and subcellular location of VGSCs have previously 
been proposed to induce hyperexcitability in DRG neurones (Matzner and 
Devor 1992, Devor, Govrinlippmann and Angelides 1993). Thus, suggesting 
that changes are occurring at the level of the neurites or potentially the 
regulation of other channels responsible for effects on excitability. 
 
3.3.1 Inflammatory soup induces hyperexcitability in 
DRG neurones 
Increased pain response from inflamed tissue results from exposure of 
inflammatory mediators released at the site of injury and consequent 
nociceptor sensitisation (Ji and Strichartz 2004). In the context of hyperalgesia 
(subject response), these are characterised by decreased pain threshold, 
increased pain in response to suprathreshold stimuli and spontaneous pain 
(Meyer and Campbell 1981). On the other hand, the sensitisation of 
nociceptors (fibre response) is characterised by a decrease in the threshold 
for action potential firing, increased firing to suprathreshold stimuli and 
spontaneous activity (Cummins et al. 2009). Hence, in this in vitro model of 
inflammation, these parameters were evaluated as hallmarks for 
hyperexcitability. 
 
Many of the inflammatory mediators included in the IS have been shown to act 
directly on DRG neurones and alter excitability (section 1.5). Indeed, in Figure 
3.1 the IS induced hyperexcitability in DRG neurones (Figure 3.1). One of the 
inflammatory modulators that have been more studied is PGE2. PGE2 has 
been shown to modulate Nav1.8 currents, HCN current and suppress K+ 
conductance (Momin and McNaughton 2009, Gold et al. 1998, Nicol et al. 
1997). These phenomena are believed to occur via cAMP-PKA-PKC signalling 
cascades (England et al. 1996, Evans, Vasko and Nicol 1999, Gold et al. 
1998). PKC inhibitors have been shown to decrease the TTX-R Na+ density, 
although, there is some debate towards the contribution of TTX-R in DRG 
excitability in vivo as PKA and PKC may serve as a common signalling for the 
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modulation of other physiological processes (Gold et al. 1998, Zheng et al. 
2007). In fact, it has been demonstrated that changes in sodium currents only 
play a minor role and that PGE2’s main effect on firing frequency is via 
enhanced hyperpolarisation-activated inward current through cAMP 
modulation. PGE2 changes shifts the voltage sensitivity to a more positive 
voltage which essentially enhances the inward current between the resting 
membrane potential and action potential threshold. Thus, neurones are 
thought to depolarise more regularly (Matsutomi et al. 2006). In my data set, I 
recorded from IB4-negative DRG neurones, and there is evidence to suggest 
PGE2 receptors are expressed in this subgroup (Usoskin et al. 2015, Lin et al. 
2006, Ng et al. 2013). Hence, it is likely that modulation by PGE2 contributes 
to increased excitability. Likewise, IB4-negative DRG neurones express TrkA, 
the NGF receptor. In culture, NGF supplementation has also been shown to 
alter DRG excitability. Overnight incubation with 100 ng/mL NGF has been 
demonstrated to induce hyperexcitability (in this thesis IS: 50 ng/mL NGF) 
which is observed for up to 8 days (Kitamura et al. 2005). NGF is a known 
modulator of TTX-R currents (Fjell et al. 1999a, Leffler et al. 2002, Okuse et 
al. 1997, Kerr et al. 2001, Gold et al. 1996, Zhang et al. 2002) and these have 
been shown to be the main component in action potential generation 
(Matsutomi et al. 2006). Furthermore, serotonin incubation has been 
demonstrated to induce excitability DRG neurones. Multiple studies have 
confirmed its role on TRPV1 sensitisation, but 5-HT2C receptor activation has 
also shown modulation of calcium-activated Cl- channels (Salzer et al. 2016). 
However, these were acute applications of serotonin (60 s), and in this data 
set, incubations were set for 22h. If these mechanisms are contributing to the 
hyperexcitability observed is not known. Moreover, addition of bradykinin to 
DRG cultures has also been shown to depolarise DRG neurones (Jeftinija 
1994, Rang and Ritchie 1988) and to primarily affect IB4-negative neurones 
(Devesa et al. 2014), and addition of ATP to increased DRG excitability via 
P2Y receptors (Malin and Molliver 2010, Yousuf et al. 2011). One significant 
difference in this thesis is that these mediators were added together to the 




Previous in vitro studies have established that treatment of nociceptors with 
an inflammatory soup increases neuronal excitability (Maingret et al. 2008, 
Zhao et al. 2010). Maingret et al. 2008 have used gene targeting and computer 
modelling to identify Nav1.9 channel current signature and its impact on DRG 
excitability in acutely dissociated DRG neurones. They report increased 
Nav1.9 current after 3 min of continuous incubation with inflammatory 
mediators (50 nM bradykinin, 500 nM prostaglandin E2, 1 µM histamine, 500 
nM noradrenaline and 2 µM ATP) which remains until the last measured time 
point, 12 min. They demonstrate via knockout mice that TTX-R current 
increase is via Nav1.9 and not Nav1.8.  Interestingly, they also report that only 
when the inflammatory soup components are applied together, and not each 
element individually, the Nav1.9 current increases. Thus, the cocktail of 
inflammatory mediators acted synergistically to modulate Nav1.9. The authors 
suggest a converging action of PKA and PKC pathways behind the enhanced 
excitability but also a minor inhibition of K+ currents (Maingret et al. 2008). This 
increase in Nav1.9 mediated Na+ current contributes to subthreshold 
amplification and increased excitability. In a different set of experiments, Zhao 
et al. 2010 showed that incubation with an inflammatory soup that contained 
bradykinin, prostaglandin E2, histamine, ATP, and 5-HT induced increased 
excitability in wild-type DRG neurones but not in dicer null Nav1.8 positive 
neurones. Dicer enzyme controls multiple gene transcripts, and their study 
identifies a role in altering pain thresholds (Zhao et al. 2010).  
 
Increases in channel currents and excitability may also result from increased 
trafficking and membrane insertion of channel proteins into the plasma 
membrane. In support of such a mechanism, a recent report by Huang et al. 
2016 provided evidence that inflammatory mediators increased recruitment of 
Cav3.2 to the plasma membrane. Overnight incubation with 2 µM ATP and 
100 nM bradykinin has revealed an increase in T-type Ca2+ channels in DRG 
neurones. The authors suggest these inflammatory mediators trigger the 
recruitment of a reserve pool of Cav3.2 (Huang et al. 2016). In this chapter’s 
IS 2 µM ATP and 50 nM bradykinin were included in the inflammatory insult 
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hence it is possible that a similar mechanism is occurring but whether this plays 
a part in IS induced hyperexcitability is unknown. While mechanisms for 
hyperexcitability are expected to be similar to Maingret et al. 2008, due to 
similar inflammatory soup recipes, it is likely that second messenger events 
are happening. For example, the release of further inflammatory mediators 
from paracrine interaction, and an interplay between non-neuronal cells (e.g. 
satellite glial cells) are contributing to the hyperexcitability induced by IS. 
 
One component that contributed to IS-induced hyperexcitability is the 
reduction of action potential threshold (Figure 3.1 C). The contribution to the 
threshold of action potential firing in DRG neurones is thought to be mainly via 
Nav1.9 and Nav1.7. Extensive evidence supports that VGSC Nav1.9 currents 
are heavily modulated in inflammation and can crucially change firing 
thresholds in small diameter nociceptors (Rush and Waxman 2004, Maingret 
et al. 2008, Baker et al. 2003, Coste et al. 2004). Nav1.9 null mice have been 
shown to have reduced PGE2 hypersensitivity (Priest et al. 2005) and reduced 
sensitivity to inflammatory mediators such as PGE2, bradykinin, serotonin, and 
ATP but not NGF (Amaya et al. 2006). In this data set, small diameter DRG 
neurones were chosen, and these have been shown to express Nav1.9 (Dib-
Hajj et al. 1998). A common second messenger of GPCRs activated by PGE2, 
ATP, and 5-HT is GTP, and it has been shown to up-regulate Nav1.9 persistent 
currents and induce repetitive firing (Baker et al. 2003, Ostman et al. 2008). 
On the other hand, Nav1.7 is also thought to set the threshold of action 
potentials in nociceptors. Nav1.7’s role is supported by knockout and shRNA 
studies where hyperalgesia is reduced (Nassar et al. 2004, Yeomans et al. 
2005), and loss-of-function mutations associated with congenitive insensitivity 
to pain (Cox et al. 2006, Goldberg et al. 2007). Importantly, Nav1.7 is 
upregulated in models of inflammatory pain (Tanaka et al. 1998, Black et al. 
2004). Furthermore, serotonin has been reported to reduce action potential 
threshold and increase excitability via cAMP coupled to TTX-R currents, those 
mediated by Nav1.8 and Nav1.9 (Cardenas et al. 2001).  Hence, it is possible 
that the changes in threshold are due to Nav1.9 persistent current, 
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Nav1.7/Nav1.9 channel upregulation or direct modulation by second 
messengers such as PKA, PKC and GTP. 
 
3.3.2 Inflammatory soup does not significantly alter 
action potential properties but alters timing of the first 
action potential at rheobase. 
Action potentials result from an interaction of multiple voltage-dependent 
conductances expressed by neurones. In the mammalian brain these 
commonly include components of voltage-dependent Na+ currents, voltage-
dependent Ca2+ currents, voltage-activated K+ currents, calcium-activated K+ 
currents and the hyperpolarisation-activated current (Bean 2007). Because the 
IS induced hyperexcitability in isolated DRG neurones (Figure 3.1) it would be 
expected that one of the action potential voltage-dependent conductances, 
which led to increased excitability, would be altered and thus detected in the 
action potential threshold measurements. Current clamp data showed a 
significant reduction in current necessary for action potential firing (Figure 3.1 
C), but individual analysis of each action potential from each recorded neuron 
did not (Figure 3.2 A). 
 
Other studies have reported changes in action potential shape in the context 
of inflammation and hyperexcitability. In a rat CFA model of inflammation, NGF 
sequestration reduced the effects of inflammation on in vivo action potential 
duration at base and firing frequency (Djouhri et al. 2001). In Figure 3.2 F, IS 
also seems to decrease the action potential duration at rheobase. Axotomy, 
which is necessary for DRG culture, changes the excitability and action 
potential waveform of DRG neurones (Gurtu and Smith 1988, Devor and Wall 
1990, Oyelese et al. 1997) so it limits the perspective of these action potentials 
to those acquired in vitro. It is, however, changes in latency, measured as the 
interval between the start of the protocol and peak of the action potential, that 
is significantly different (Figure 3.2 G). The IS significantly reduces the latency 
at twice rheobase for the generation of the action potential, suggesting 
changes in Nav1.9 activity. Similar findings were reported when inflammatory 
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mediators were added acutely to DRG neurones in Nav1.9 -/- and WT. This 
reduction in latency is likely due to Nav1.9 current potentiation (Maingret et al. 
2008). 
 
3.3.4 Inflammatory soup (6 h) increases TTX-R sodium 
currents 
As previously mentioned, inflammatory mediators have been shown to 
increase TTX-R currents in DRG neurones in both in vivo and in vitro studies 
(Gold et al. 1996, Maingret et al. 2008, Omri and Meiri 1990). Hence, these 
results were expected. What it was not known was whether a single 
inflammatory insult would have such impact even after 6 h. As Maingret and 
colleagues reported, it is likely that a mechanism involving both PKA and PKC 
underlies the upregulation of Nav1.9 TTX-R currents seen during acute 
applications. Hence, it is not clear if these changes depicted in Figure 3.6, 
incubation with IS for 6 h as opposed to acute, are due to modulation of the 
channel’s activity or increased channels at the plasma membrane. There is no 
current direct evidence of trafficking of Nav1.9 as an effect of the inflammatory 
soup in vitro.  
 
In contrast, no significant changes were observed in TTX-S sodium current. 
Nav1.7, a TTX-S channel, has been linked to inflammatory conditions (Nassar 
et al. 2004, Abrahamsen et al. 2008). The absence of TTX-S current increase 
may reflect a limitation of the in vitro model or of the data acquisition. It has 
been previously reported in a combined voltage and current clamp study that 
TTX-R/slow Na+ current plays a major role in action potential generation 
evoked by current injection protocols but from a resting membrane potential of 
-70 mV. The TTX-S component in action potential generation was only 
detected when the membrane was held at -100 mV (Matsutomi et al. 2006). In 
this thesis the DRG neurones were held at -70 mV as small mouse DRG 
neurones have a typical resting membrane potential of -70 to -50 mv at the 
soma, only in certain pathological conditions the membrane may be 
excessively hyperpolarised (Matsutomi et al. 2006).   
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3.3.5 Does Inflammatory (6 h) soup induce trafficking 
of VGSC to the plasma membrane? 
There are nine VGSC (Nav1.1 – Nav1.9), but only three sodium channels 
(Nav1.7, Nav1.8 and Nav1.9) are associated with DRG neurones and pain 
disorders (Eijkelkamp et al. 2012). In addition to Nav1.7-Nav1.9, the Navb4 
subunit was also included due to its role in the regulation of fast-resurgent 
currents and excitability in DRG neurones (Barbosa et al. 2015). Interestingly, 
the IS induced changes in the expression of VGSC, the Nav1.7’s and Nav1.9’s 
expression levels at the soma plasma membrane decreased (Figure 3.5, 3.6 
and 3.7). At first, these changes were the opposite of what was expected, an 
increase in VGSC expression at the plasma membrane or the expression to 
remain the same, as current clamp recordings depicted increased excitability 
(Figure 3.1). I hypothesised that if there were changes induced by the IS 
regarding expression, it would be an increase in expression. However, location 
is also critical. Changes in the density and subcellular location of VGSCs have 
previously been proposed to induce hyperexcitability in DRG neurones 
(Matzner and Devor 1992, Devor et al. 1993, Waxman and Ritchie 1985).  
 
Previous studies support this view of the increased expression of VGSC 
following inflammation (Black et al. 2004, Tanaka et al. 1998, Strickland et al. 
2008). There is evidence to suggest inflammation induced upregulation in vivo 
of both TTX-R and TTX-S VGSCs. Therefore, these results could indicate that 
the time window of observation chosen is a period of desensitisation. For 
instance, in the context of long-term potentiation, central neurones adapt by 
changing the composition of the plasma membrane and internalise some 
receptors (Collingridge, Isaac and Wang 2004). Current clamp data depicts 
hyperexcitability at 6 h (Figure 3.3). In other pain syndromes such as nerve 
injury, TTX-R VGSCs have been shown to be downregulated in parallel with 
TTX-S VGSCs upregulation (Cummins and Waxman 1997). It is possible that 
the biophysical properties of the DRG neurones have changed via other 
mechanisms such as activation of M channels (Du et al. 2014).  
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The effects of IS on TRPV1 plasma membrane expression were also assessed 
(Figure 3.8). Likewise, the expression of TRPV1 is significantly reduced after 
6 h incubation with IS. In line with VGSCs, previous studies on TRPV1 
regulation have also described an increase in expression in animal models of 
inflammation (Yu et al. 2008), and fusion of vesicles containing TRPV1 
following bradykinin (Mathivanan et al. 2016) or ATP (Devesa et al. 2014) in a 
SNARE regulated process. Hence, these data (Figure 3.7 and Figure 3.8) 
seem to contradict what has been described. However, as with VGSCs, the 
location of TRPV1 is also important. In an in vivo setting, these would be found 
mainly in the free nerve endings in the skin (Szallasi and Blumberg 1999). In 
the study by Mathivanan et al. 2016, exocytosis of TRPV1 channels driven by 
1 µM bradykinin was impaired by the peptide DD04107, which impairs 
regulated exocytosis. Whole-cell recordings of IB4-negative neurones showed 
acutely the effects of this peptide (Mathivanan et al. 2016). Technically, soma 
whole-cell recordings clamp the whole cell, but there may be some current 
flowing between neurites that is not detected so this exocytosis effect must be 
at the level of the soma. Given that these are acute observations it is possible 
that in this thesis’ inflammation model, the fusion of primed vesicles, such as 
those in Mathivanan 2016, do occur in the first instance. However, given a 
longer period of incubation, these vesicles might relocate, if initially found at 
the soma, to the neurites of the neurones, which is where they are mainly found 
in vivo (Szallasi and Blumberg 1999) or the combined effects of this thesis’ IS 
lead to receptor desensitisation and internalisation. One possible approach to 
follow these experiments is to add tumour necrosis factor - a (TNF-a) to DRG 
neurones.  A recent study has described TRPV1 upregulation in the soma of 
trigeminal ganglion neurones after 24 h incubation with 100 ng/mL TNF-a 
(Meng et al. 2016). 
 
3.3.6 Inflammatory soup incubation (6 h) does not alter 
VGSC protein expression 
Following the unexpected results on the expression of VGSCs, I hypothesised 
that this decrease in the expression of Nav1.7 and Nav1.9 at the level of the 
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soma was a consequence of subcellular redistribution. Although it does not 
address this hypothesis directly, I set out to analyse changes in protein 
expression of both Nav1.7 and Nav1.9 following the in vitro incubation with IS 
to evaluate possible transcriptional regulation changes. No significant changes 
were seen in the protein expression of Nav1.7. Regrettably, technical issues 
did not permit the detection of Nav1.9. Thus, the IS incubation induced 
hyperexcitability of IB4 negative DRG neurones (Figure 3.3) while maintaining 
the same level of Nav1.7 expression (Figure 3.9). Yet, channel’s expression 
at the plasma membrane of DRG soma is significantly reduced in IB4-negative 
neurones. 
 
Nav1.7, Nav1.8 and Nav1.9 are distributed across the soma and the neurites 
of DRG neurones (Black et al. 2012, Fukuoka et al. 2008). As previously 
mentioned, action potential shape of neurones may vary if recorded at the level 
of processes or soma. Evidence suggests nociceptor afferents have a resting 
membrane potential (Vrest) of -40 mV and at the soma between -50 and -75 
mV (Baccaglini and Hogan 1983, Gold et al. 1996). Furthermore, computer 
modelling has shown that increased VGSC density may cause 
hyperexcitability (Matzner and Devor 1992) and that VGSCs accumulate at the 
site of injury (Matzner and Devor 1994, Devor et al. 1993). Thus, it is possible 
that Nav1.7 and Nav1.9 are redistributed following incubation with IS. Although 
the experiments in this chapter did not test this hypothesis directly there is 
evidence that this occurs in nerve injury (England et al. 1994, Devor et al. 1993, 
Lombet et al. 1985) and in CFA models of inflammatory pain, for voltage-gated 
Ca2+ channels (Lu et al. 2010).   
 
3.3.7 General discussion and future directions 
The inflammatory mediators in the IS induced hyperexcitability in DRG 
neurones. Though, there is a major caveat to these experiments. These 
recordings were clamped at the level of the soma, and thus demonstrate that 
TTX-R Na+ currents are increased at the level of the soma following the 
incubation with these inflammatory mediators. The functional relevance of 
somatic depolarisation of DRG neurones is still not completely understood.  
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There is evidence that somatic depolarisation is involved in nociceptor 
sensitisation and ectopic activity (Amir and Devor 1996, Shinder, Amir and 
Devor 1998, Liu, Amir and Devor 1999, Utzschneider, Kocsis and Devor 1992) 
but the function of TTX-R Na+ currents during axonal propagation of action 
potentials is disputed. In vitro, somatic TTX-R Na+ currents have been shown 
to be a major component of the action potential (Matsutomi et al. 2006), and 
there is evidence of TTX-R Na+ currents in axons in C-fibres (Quasthoff et al. 
1995). However, axonal propagations are blocked by TTX (Ritter and Mendell 
1992, Villiere and McLachlan 1996) but only 15% of C-fibres. However, when 
all the experiments of this chapter are considered, IS induces hyperexcitability 
and increase in TTX-R but Nav1.7 and Nav1.9’s expression decreases at the 
soma plasma membrane. Thus, suggesting that subcellular location of these 
channels is likely having an impact. In a recent study by Branco et al. 2016, 
they demonstrated that synaptic integration by Nav1.7 is critical in 
hypothalamic neurones.  A persistent current by Nav1.7 specifically prolonged 
the excitatory postsynaptic potentials making the synaptic integration by these 
cells unique. However, knockdown of Nav1.7 observed no changes in 
threshold for action potential or transient Na+ current recordings, suggesting a 
dendritic location of Nav1.7 (Branco et al. 2016).  
 
Following up these results, it would be beneficial to characterise 
pharmacologically (e.g. Protoxin II, Nav1.7 antagonist) the components of the 
currents measured in voltage-clamp and further understand the contribution of 
each a-subunit. Likewise, analysis of the expression of each a-subunit at the 
level of the neurites via immunocytochemistry. Overall, the signalling pathways 
and the effects of the inflammatory soup are not yet well characterised, but 
further understanding might reveal interesting targets regulating the 









SNARE proteins mediate the ubiquitous phenomenon of vesicular fusion. This 
phenomenon is crucial for the transport of cargo within the cell, cargo release 
to the extracellular medium, and for plasma membrane maintenance (Schoch 
et al. 2001, Rao et al. 2004, Jurado et al. 2013). The SNARE family has been 
mainly studied in the central nervous system (CNS) in the context of 
neurotransmitter release. In the brain, VAMP2 is an abundant v-SNARE 
protein interacting with t-SNARE proteins such as syntaxin-1 and SNAP-25 
(Takamori et al. 2006).  Nevertheless, other v-SNAREs such as VAMP7 have 
also been shown to participate in neurotransmission in the CNS (Bal et al. 
2013). Evidence suggest different v-SNAREs might be segregating different 
vesicular pools (Deitcher et al. 1998, Hua et al. 1998, Sara et al. 2005, Revelo 
et al. 2014).  
 
In DRG neurones, vesicular fusion at nerve endings and in the spinal cord is 
crucial for nociception. During inflammation and pain processing not only is 
there the release of neurotransmitters and inflammatory mediators, but several 
ion channels and receptors may also be delivered to the plasma membrane 
(Black et al. 1999, Tanaka et al. 1998, Garry and Hargreaves 1992, Karanth 
et al. 1991, Kilo et al. 1997, Meng et al. 2016). Hence, identifying the v-
SNAREs mediating vesicular fusion in DRG neurones will substantially 
improve our basic understanding of how vesicular trafficking is organized and 
regulated in nociception but also provide insight to the development of new 
drugs that may target specific vesicular trafficking pathways contributing to the 
establishment of a chronic pain state. 
 
Previous studies have indicated mRNA expression of all seven VAMP isoforms 
in DRG neurones (Chiu et al. 2014, Thakur et al. 2014, Usoskin et al. 2015). 
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In addition, Rouwette et al. 2016a have profiled 3067 proteins expressed in 
DRG, and found evidence for seven VAMP proteins (Rouwette et al. 2016b). 
VAMP-1 and -2 have been described in regulated secretion of CGRP in rat 
trigeminal ganglia. They were found on CGRP-containing vesicles but forming 
different SNARE complexes (Meng et al. 2007). At the start of my project, 
major DRG profiling studies were still unpublished thus the aim of the work 
described in this chapter was to identify the VAMP isoforms in DRG neurones.  
 
4.2 Results 
4.2.1 Isolated DRG cultures express mRNA for all 
VAMP isoforms 
DRG neurones were isolated and cultured for 72 h (N=2) (experiments by Drs 
Seward, Bauer and Nassar). Total RNA was extracted and processed by Paul 
Heath form Sheffield Institute for Neuroscience (details section 2.8). Statistical 
analysis was accomplished by Dr Marta Milo. Due to the low number of 
samples, probability of positive log-ratio (%) was calculated and indicates the 
presence of all VAMP isoforms in isolated DRG neurones (Figure 4.1). 
 
Figure 4.1 RNA expression in mouse DRG neurones. 
Isolated DRG neurones were cultured for 3 days in standard cultured medium and harvested 
for mRNA identification (These experiments were conducted by Drs Seward, Bauer and 


































4.2.2 Whole DRG express VAMP-1, -2, -3, -4, -5, and -7 
Since the microarray results strongly suggest that all isoforms were being 
expressed at mRNA level (Figure 4.1) further experiments were necessary to 
confirm this at the protein level. Thus, western blotting was performed to 
identify the VAMP proteins on whole DRG lysate.  Since the majority of the 
literature has demonstrated the presence of VAMP proteins in the CNS, brain 
lysates were added for comparison (Figure 4.2). All isoforms but VAMP8 were 
detectable in DRG neurones by western blot and were identified within the 
predicted molecular size for each isoform (VAMP-1, -2, -3, -5 and -8 close to 
12 kDa and VAMP7 close to 25 kDa, see table 1.2). After quantifying 3 repeats, 
VAMP-1 and -2 were found to have a lower expression level than brain lysate 
(0.39 ± 0.07 and 0.03 ± 0.007, respectively); in contrast, VAMP-3, -4, -5 and -
7 were highly expressed in DRGs when compared to the brain (12.3 ± 11.04, 
5.03 ± 1.05, 4.5 ± 0.7 and 5.59 ± 0.63, respectively, Figure 4.3).  
 
Lysates from other tissues were used to evaluate the antibodies’ selectivity. 
Tissues selected had previously been reported to be enriched with a specific 
isoform. Namely, spleen is enriched with VAMP3 (McMahon et al. 1993), heart 
with VAMP5 (Zeng et al. 1998), and lung with VAMP7 (Braun et al. 2004). In 
addition, a HeLa cell line lysate was used to confirm anti-VAMP8 antibody 
sensitivity (Wong et al. 1998). Several concentrations of brain and DRG lysate 
were used to detect VAMP8 and the highest (58 µg) is shown on figure 4.2. 
Nevertheless, VAMP8 could not be detected by western blot. In addition, non-
commercial antibodies (VAMP4, -7, and-8) were previously tested against 
knockout samples and shown to be specific (data not shown, Dr Andrew 




Figure 4.2 Western blots depicting protein expression of VAMP isoforms.  
Lysates were obtained from whole dorsal root ganglia (not cultures). Other mouse tissues 
were also lysed and used as positive controls (brain, spleen, heart and lung) as well as HeLa 
samples. All blots were probed for GAPDH and b-III tubulin in addition to VAMP isoforms. All 
isoforms except VAMP8 were detected in DRG samples. All immunoblots were repeated at 





Figure 4.3 The expression ratio of the different VAMP isoforms in DRG compared to 
brain.  
The median intensity of the immunoblot bands indicating VAMP expression in DRG was 
divided by the median intensity of the respective bands in the brain lysate. VAMP1 and VAMP2 
were found to have a lower expression when compared to the brain whereas VAMP-3, -4, -5 
and -7 had a higher expression. Error bars show SEM (nVAMP1=3, nVAMP2=3, nVAMP3=3, 
nVAMP4=4, nVAMP5=3, nVAMP7=3).  
 
4.2.3 VAMP-1, -2, -3, -4, -5, -7 and -8 are expressed in 
the soma of isolated DRG neurones. VAMP-1, -2 and -7 
in the neurites. 
Both mRNA microarray and western blotting experiments demonstrated the 
presence of VAMP isoforms in DRG neurones. With the exception of VAMP8 
all were detected in the immunoblots. However, the samples used for lysing 
were from either mixed cultures (microarray) or whole DRG lysates (western 
blot). It was still possible that the mRNA or protein detected was from non-
neuronal cells. Hence, isolated DRG neurones were cultured for 24h, fixed and 
probed against all VAMP isoforms and the pan neuronal marker b-III tubulin 




































Figure 4.4 Representative images of VAMP expression in DRG neurones in culture.  
Isolated DRG neurones were cultured for 24 h. Immunocytochemistry was performed to 
identify the subcellular location of VAMP isoforms (green) in DRG neurones positive for b-III 
tubulin(red) and DAPI for nuclei (blue). Details of the antibodies used can be found at section 
2.4.1. Images were acquired using “Deltavision RT system” (Applied Precision, Issaquah, 
Washington) and were further processed by deconvolution. No primary antibody controls were 
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used to account for DRG neurones’ autofluorescence by adjusting acquisition settings. Images 
shown are the maximum intensity of the respective z-stack. Scale bars show 20 µm and arrows 
indicate VAMP staining in neurites. 
 
Interestingly, all VAMP isoforms were detected in the immunocytochemistry of 
DRG neurones, even VAMP8 (Figure 4.4). Most of the staining for VAMP 
isoforms could be seen in the soma of the DRG neurones. Exceptionally, 
VAMP-1, -2 and -7 were also seen in the neurites of DRG neurones (Figure 
4.4 arrows). On the other hand, most of the isoforms were detected in b-III 
tubulin negative cells with the exception of VAMP7 (data not shown). VAMP4 
was found close to the nucleus and it is in agreement with its previously 
described role in the trans-Golgi network (Peden et al. 2001). 
 
To further understand the proportion of DRG neurones expressing VAMP 
isoforms, an automated system was used to quantify expression. Of a total of 
5515 isolated DRG neurones analysed 90 ± 8 % expressed VAMP8, 82  ± 8 
% VAMP3, 90 ± 160 % VAMP1, 78 ± 12 % VAMP2, 71± 12 % VAMP4, 50 ± 
16 % VAMP5 and 35 ± 12 % VAMP7 (Figure 4.5 B). Hence, VAMP5 and 





Figure 4.5 Quantification of VAMP expression across soma diameters. 
Isolated DRG neurones were cultured for 48h. Immunocytochemistry was performed to 
identify VAMP isoforms in b-III tubulin positive DRG neurones in culture. An automated 
system, InCell analyser 2200 (GE healthcare), was used to quantify the number of DRG 
neurones positive for each VAMP isoform and each DRG neurone’s soma diameter was 
measured. (A) Histogram summarising the distribution of soma sizes measured (n=5515). (B) 
The percentage of DRG neurones positive for each VAMP isoform. (C) The percentage of 
DRG neurones positive for each VAMP isoform across different soma diameters. Error bars 
show SEM. 
 
4.2.4 VAMP isoform expression is consistent across 
soma diameter 
DRG neurones may be subdivided according to distinct response 
characteristics, chemical markers, modalities of stimulation and soma 
diameter (Lawson and Waddell 1991, Stucky and Lewin 1999, Slugg et al. 
2000). Nociceptors have been demonstrated to have a smaller mean soma 
diameter compared to other primary fibres (Lawson and Waddell 1991). 
























































































Hence, VAMP expression was also analysed against soma diameter (Figure 
4.5 C). Each cell body was measured according to b-III tubulin staining and an 
average diameter (Feret’s analysis) per neurone was calculated. It is worth 
noting that these data derive from isolated DRG neuronal cultures. Thus, larger 
soma diameters are less well represented in culture as these are more difficult 
to isolate (Figure 4.5 A). Taken together these data demonstrate ubiquitous 
expression of VAMP-1, -2, -3, -4 and -8 across different DRG soma diameters. 
In contrast, VAMP7 expression profile depicts a trend towards higher soma 
diameters peaking at 25 µm and VAMP5 towards 20 µm. 
 
4.2.5 Is Nav1.7 found within vesicles with specific 
VAMP isoforms? 
Compelling evidence suggest the involvement of Nav1.7 in pain signalling 
(Ahmad et al. 2007, Cox et al. 2006, Goldberg et al. 2007). To date the 
SNAREs, including VAMPs, involved in Nav1.7 trafficking remain unknown. 
Thus, DRG neurones were isolated and probed with anti-Nav1.7 and anti-
VAMP in the process of immunocytochemistry (Figure 4.6). As expected 
Nav1.7 fluorescence can be seen in the neurites and at the plasma membrane 
of DRG neurones. The aim was to identify vesicles containing the a-subunit 
Nav1.7. Yet, statistical analysis did not indicate a specific VAMP isoform to co-
localise with Nav1.7 and thus likely involved in the channel’s trafficking in DRG 
neurones (Figure 4.7). 
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Figure 4.6 Representative images of VAMP expression and Nav1.7 in DRG neurones. 
Isolated DRG neurones were cultured for 24h. Immunocytochemistry was performed to assess 
the co-localisation of VAMP isoforms (green) and the voltage-gated ion channel Nav1.7 (red). 
DAPI was used to identify nuclei (blue). Images were acquired using “Deltavision RT system” 
 100 
(Applied precision, Issaquah, Washington) and z-stack of each cell were further processed by 
deconvolution. No primary antibody controls were used to account for DRG neurones’ 




Figure 4.7 Quantification of the co-localisation of VAMP isoforms with Nav1.7 by 
Pearsorn’s coeffiecient analysis. 
A selection of at least 10 somata per mouse per isoform were analysed with ImageJ’s co-
localisation analysis plug in JACoP (N=5). Background was subtracted by analysing a flipped 
imaged of the same soma. Data not significantly different (One-way ANOVA). Error bars show 
standard error of the mean. 
 
4.3 Discussion 
Vesicular fusion is a key event for pain signalling as it is the mechanism 
underlying neurotransmitter release and ion channel trafficking (Garry and 
Hargreaves 1992, Karanth et al. 1991, Martling et al. 1988, Suedhof 2013). 
For instance, increased expression of voltage-gated ion channels at the 
plasma membrane changes excitability of DRG neurones (Black et al. 1999, 
Tanaka et al. 1998). Hence, these vesicular fusion events are important for the 
fine tuning of the pain signalling. Evidence suggests v-SNAREs may 
participate in differentiating vesicular populations within the cell. Thus, to 
further understand the role of v-SNAREs in DRG neurones, experiments in this 
chapter were designed to identify and characterise the expression of VAMP 
isoforms. Firstly, a microarray analysis of the mRNA was performed in isolated 
DRG neurones. Followed by western blotting analysis of protein expression 







































4.3.1 Isolated DRG cultures express mRNA for all 
VAMP isoforms 
The microarray results in this chapter strongly suggest expression of VAMP1-
8 (Figure 4.1). This is in agreement with recent studies published in the interim 
of this project which have also indicated a similar expression profile. Using 
single cell RNA-seq Usoskin et al. 2015 unbiasedly grouped DRG neurones 
according to their expression profile; Thakur et al. 2014 have used a novel 
application of magnetic cell sorting (MAC) to isolate nociceptors and compared 
them to other DRG neuronal subtypes, and Chiu et al 2014 have used two 
mouse reporter lines to identify and purify a subset of DRG neurones in 
combination with IB4 surface labelling. Importantly, these three studies have a 
common message regarding VAMP mRNA expression. They all identified the 
7 isoforms but have used slightly different preparations. Usoskin et al. 2015 
and Chiu et al. 2014 only included in their analysis L4-L6 ganglia whereas 
Thakur et al. 2014 pooled from all the ganglia. This can be a limitation for both 
approaches. On one hand, by using a specific subset we learn the ganglia’s 
specific set but caution should be used when extrapolating it for other ganglia. 
On the other hand, it has been suggested that certain anatomical regions are 
potentially more enriched for certain transcripts (e.g. lumbar vs cervical) and 
may introduce an error (Chiu et al. 2014). Nevertheless, it is important to 
mention that the results presented in this project are from a mixed culture of 
both neuronal and non-neuronal cells from all regions. Although it is possible 
to ‘enrich’ DRG cultures with neurones with the use of mitotic inhibitors and 
extended cultures (more than a week) these are often not used as off-target 
effects on neurones by inhibitors and changes in protein expression over the 
course of prolonged culture are a concern (Buschmann et al. 1998, Malin, 
Davis and Molliver 2007, Wallace and Johnson 1989, Scott and Edwards 
1980). Ideally, approaches used by other labs such as unbiased RNA-seq or 
MACS sorting could have been used to improve these results but it was not a 
possibility. Hence, the “impurity” of DRG cultures is a significant limitation of 
these results. Taken together these studies (Chiu et al. 2014, Thakur et al. 
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2014, Usoskin et al. 2015) and the results discussed here strongly support the 
idea of a complete mRNA VAMP expression by DRG neurones. 
 
4.3.2 Whole DRG express VAMP-1, -2, -3, -4, -5, and -7 
Immunoblot analysis showed expression of VAMP-1, -2, -3, -4, -5, and -7 
(Figure 4.2). Given the results of the microarray (Figure 4.1) and what has now 
been published (Chiu et al. 2014, Thakur et al. 2014, Usoskin et al. 2015) it 
was expected that all isoforms would be detected. This was not the case for 
VAMP8. One possibility is that the preparation used might be altering the data 
set to a false negative. That is, there is the possibility that non-neuronal cells 
present in the lysate may be skewing the expression down or perhaps the 
expression level is below the detection level of the western blot technique. To 
confirm this, other techniques could be used such as mass spectrometry. 
Indeed, in the proteomics study by Rouwette et al. 2016 they demonstrated 
the expression of the VAMP8 protein in DRG neurones. 
 
Another interesting observation is the varying levels of expression of each 
isoform (Figure 4.3). When compared to the brain lysate, VAMP-1 and -2 had 
a lower expression level. These are two known abundant SNAREs in the CNS 
tightly linked to vesicular fusion with the plasma membrane (Schoch et al. 
2001, Raptis et al. 2005, Takamori et al. 2006). Both have been described in 
slightly different areas and associated with different vesicular fusion events. 
For instance, NMDA receptor trafficking to plasma membrane is mediated by 
VAMP1 in hippocampal neurones (Gu and Huganir 2016) and VAMP2 
mediates BDNF release in cortical neurones (Shimojo et al. 2015). The other 
VAMP isoforms, VAMP-3, -4, -5, -7 and -8, had a higher expression in DRG 
when compared to the brain lysate. One possible explanation, is that brain 
tissue used includes the neurones and supporting cells with their synapses 
whereas dorsal root ganglia lysate does not have its synapses to the spinal 
cord or the nerve endings at the dermis and other innervating organs. Hence, 
subcellular locations expected to be enriched with neurotransmitters may have 
not been included. That is, assuming that the same v-SNAREs are mediating 
the neurotransmitter release in DRGs. For instance, VAMP1 and VAMP2 have 
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been described in CGRP secretion from trigeminal neurones (Meng et al. 
2007). Furthermore, differences in neuronal density between the tissues might 
influence the data. For example, neuronal density has been reported to vary 
between different cortical areas (Collins et al. 2010) 
 
To confirm the antibodies specificity positive control tissues were used in 
parallel. Spleen due to its high levels of VAMP3 (McMahon et al. 1993), heart 
of VAMP5 (Zeng et al. 1998), lung of VAMP7 (Braun et al. 2004) and HeLa 
cells of VAMP8 (Wong et al. 1998). This proved particularly useful for detecting 
VAMP8 as DRG lysates used did not show any immunoreactivity. It 
demonstrates that the antibody used for VAMP8 was by definition working and 
it appears to be specific. The detection of VAMP8 was expected given the 
detection by the microarray mRNA analysis but perhaps the expression levels 
of VAMP8 in both DRG and brain are not within detection levels of western 
blotting. VAMP8 is associated with early endosomes (Wong et al. 1998) and 
in the kidney it regulates the fusion of aquaporin 2. So, it theoretically it could 
mediate the degradation of plasma membrane VGSCs in regulated 
endocytosis. 
 
4.3.3 VAMP-1, -2, -3, -4, -5, -7 and -8 are expressed in 
the soma of isolated DRG neurones. VAMP-1, -2 and -7 
in the neurites. 
Following the results of the microarray and western blotting it was important to 
identify the source of the VAMP proteins in the lysates. Immunocytochemistry 
of isolated DRG neurones depicted punctate and widespread expression of 
the seven isoforms in DRG neurones’ soma.  
 
VAMP-1 and -2 have been linked to neurotransmitter release (Borisovska et 
al. 2005) and described in trigeminal ganglion neurones as mediators of CGRP 
secretion (Meng et al. 2007). In this thesis’ immunocytochemistry both VAMP1 
and VAMP2 were observed in the soma and in the neurites. Although, DRG 
neurones do not form physiological relevant synapses in culture (Gupton and 
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Gertler 2010), they do growth neurites and are believe to form ‘synapses’ with 
other neurones in culture. To confirm their role in synaptic transmission, further 
experiments could explore co-localisation with CGRP, substance P and 
VGLUT2. In chapter 5, I have explored the role of VAMP1/2/3 and SNAP25 
with botulinum neurotoxin chimaeras. 
 
VAMP3 is ubiquitously expressed and it has been associated with sorting/early 
and recycling endosomes (McMahon et al. 1993). In DRG neurones the 
staining was mainly observed in the soma and in some cells more intense 
closer to the plasma membrane. To further understand, the putative role of 
VAMP3 in endosomes, antibodies against EEA1 (endosome maker) could be 
used to elucidate its physiological role in DRG neurones. 
 
Previous studies have stablished a role for VAMP4 in membrane trafficking in 
the transGolgi network, early/recycling endosomes (Peden et al. 2001, Mallard 
et al. 2002) and in hippocampal neurones asynchronous neurotransmitter 
release (Raingo et al. 2012). Here it is shown for the first time that VAMP4 is 
also expressed in DRG neurone somata and coherent with previous reports it 
appeared localized to nuclei and not in the neurites (Peden et al. 2001). To 
confirm this, further experiments could be performed with antibodies to 
synatxin 5 (Golgi) and calreticulum (endoplasmatic reticulum marker) to 
confirm the function of VAMP4 in sensory neurone biology.  
 
VAMP5’s role may not be as clear. This SNARE is highly expressed in skeletal 
and cardiac muscle where it has been found at the plasma membrane and 
vesicles. It is also known as myobrevin due to its role in myogenesis (Zeng et 
al. 1998). In DRG neurones, the staining was not as intense as other isoforms 
but it was also mainly found in the soma.  
 
VAMP7 has been described in neurite growth (Gupton and Gertler 2010), 
spontaneous neurotransmitter release in hippocampal neurones (Bal et al. 
2013), and linked to phagocytosis in macrophages (Braun et al. 2004). 
Interestingly, VAMP7 was only found to be expressed on DRG neurones which 
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could be highlighting a neuronal specific role. Since DRG neurones in culture 
are known not to form synapses with relevant/physiological tissues (Zarei, 
Toro and McCleskey 2004) unlike hippocampal/cortical neurones (Bal et al. 
2013) a role in synaptic transmission in DRG seems unlikely. On the other 
hand, DRG neurones in culture, particularly those treated with NGF, as I used, 
are known to rapidly extend neurites and thus it is seems likely that the VAMP7 
vesicles observed in my study could be involved in neurite expansion. This 
could be assessed with antibodies against growth associated protein 43, a 
nerve-specific protein that has been linked to the development and 
restructuring of axons (Dani, Armstrong and Benowitz 1991). 
 
Finally, VAMP8 is also believed to be ubiquitously expressed but enriched in 
epithelial cells in the lung, pancreas, intestine and kidney. It mediates 
homotypic fusion of early and late endosomes (Antonin et al. 2000b). In DRG 
neurones, the staining against VAMP8 was very broad but close to the plasma 
membrane. Co-localisation studies with EEA1 could further the understanding 
of this isoform in DRG neurones. 
 
4.3.4 VAMP isoform expression is consistent across 
soma diameter 
Nociceptors have been demonstrated to have a smaller mean diameter 
compared to other primary fibres (Lawson and Waddell 1991). These results 
(Figure 4.5) suggest a ubiquitous distribution of the isoforms throughout 
different soma diameters. Exceptionally, VAMP7 expression shows a shift 
towards 25 µm and VAMP5 to 20 µm.  Hence, the cells falling within the smaller 
diameter range (<20 µm) are likely to be nociceptors and expressing VAMP-
1, -2, -3, -4, -5, and -8. On the other hand, larger diameter (>30 µm) neurones 
associated with A-a and b fibers (Lawson and Waddell 1991) will likely express 
VAMP-1, -2, -3, -4, -7 and -8. Of all the VAMP isoforms, VAMP-1, -2, -3, 7 and 
8 are known to mediate vesicle fusion with the plasma membrane (Hasan et 
al. 2010). VAMP5 is mainly found in skeletal and cardiac muscle and its 
expression increases during myogenesis. SNARE mediated fusion analysis 
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has shown that VAMP5 does not form complexes with SNAP25/syntaxin 1 or 
SNAP25/syntaxin 5 so it is not believed to be involved in regulated exocytosis 
(Hasan et al. 2010). In contrast, VAMP7, the other divergent VAMP between 
small and large diameter DRG neurones, mediates vesicular transport from 
endosomes and lysosomes in PC12 cells (Advani et al. 1999), regulates 
secretion of interleukin-12 in dendritic cells (Chiaruttini et al. 2016) and a reelin 
sensitive vesicle pool in hippocampal neurones that augments spontaneous 
transmission (Bal et al. 2013). Thus, it could indicate a unique secretory 
pathway in this subset of DRG neurones. 
 
4.3.5 Is Nav1.7 found within vesicles with specific 
VAMP isoforms? 
Recent studies indicate that specific subsets of SNARE proteins are involved 
in the delivery of ion channels and receptors to the plasma membrane. For 
instance, NMDA receptor delivery to the plasma membrane of hippocampal 
neurones is mediated by SNAP25-VAMP1-syntaxin4 complex (Gu and 
Huganir 2016). In PC12 cells, N-type Ca2+ channels have been shown to be 
translocated to the plasma membrane via secretory vesicles after stimulation 
by high KCl solutions and ionomycin. In contrast, VAMP2 has been identified 
for trafficking AMPA receptors (Jurado et al. 2013) and TRPC3 channels 
(Singh et al. 2004). Hence, there is evidence for SNARE-mediated delivery of 
channels and receptors to the plasma membrane as opposed to constitutive 
secretion (section 1.4.9). In the context of pain processing, the co-trafficking 
of TRPV1 and TRPA1 induced by TNF-a has been described by the Oliver 
Dolly group as being mediated by SNAP25-VAMP1-syntaxin1.  These vesicles 
containing VAMP1, TRPA1 and TRPV1 contained CGRP, which suggests a 
dual role on neurotransmission and potentiation (Meng et al. 2016). Hence, it 
was postulated that a subset of VAMPs would co-localise with Nav1.7 in DRG 
neurones. 
 
Surprisingly, these data do not indicate or suggest a possible isoform 
mediating the trafficking of Nav1.7. This is likely to be a false negative. Newly 
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synthesised proteins are strongly believed to be delivered to the plasma 
membrane via SNARE regulation (section 1.4.9)(Jahn and Scheller 2006). It 
is possible that this question falls beyond the sensitivity of the method used. 
Each pixel in the images acquired is equivalent to 200 nm which far greater 
than a large dense core vesicle (Burgoyne and Morgan 2003). Other 
techniques such proximity ligation assay or higher resolution imaging such as 
OMX or Stochastic Optical Reconstruction Microscopy (STORM) could be 
used to explore this hypothesis. Another possibility is that the images were not 
acquired at the right time point. That is, most of the Nav1.7 staining was 
observed at the membrane. So, the percentage of the channel being trafficked 
at the time of fixation might be too low for detection. Therefore, the use of a 
stimulant associated with increased trafficking events of Nav1.7 could improve 
the detection and aid identification of the SNARE proteins leading to 
membrane delivery of Nav1.7. For example, exploring the effects of PKA or 
PKC modulators, second messengers of inflammatory mediators known to 
upregulate Nav1.7 currents (Black et al. 2004, Gould et al. 2004) or adding the 
inflammatory mediators to DRG cultures to increase Nav1.7 trafficking. 
 
4.4 General discussion  
These are the first set of results to describe and characterise VAMP isoforms 
in DRG neurones by western blotting and immunocytochemistry. Even though, 
further experiments such as co-localisation with peptides or other markers, and 
functionally analysis of SNARE complexes are necessary to confirm 
suggestions of functional roles made by these results. They provide an 




5 – Investigating the potential of 
Botulinum neurotoxin chimaeras to 
regulate ion channel trafficking and 
excitability in DRG neurones 
 
5.1 Introduction 
Therapeutic indications for botulinum neurotoxins have been progressively 
expanding (Abrams and Hallett 2013). BoNT/A has been useful for 
pathological conditions involving excess muscle contractions but also in the 
treatment of chronic migraine (Jackson, Kuriyama and Hayashino 2012). 
BoNT/A and BoNT/B have very defined molecular targets. BoNT/A cleaves 
SNAP25 (Matak and Lackovic 2014) and BoNTB VAMP1/2/3 (Schiavo et al. 
1992) and as a consequence prevent vesicular fusion. Hence, not only are 
they useful in a clinical setting but they are also valuable experimental tools. 
Botulinum neurotoxins have been used to further understand CGRP secretion 
from trigeminal ganglia and DRG neurones. For instance, trigeminal ganglia 
neurones have been demonstrated to require VAMP1 for CGRP secretion 
(Meng et al. 2007) and 100 nM BoNT/A pre-incubation significantly delayed 
CGRP release from trigeminal ganglia neurones in vitro (Meng et al. 2009). To 
better select the subpopulation of DRG neurones, those that are IB4 negative, 
botulinum neurotoxin chimaeras were used in this chapter. 
 
Botulinum neurotoxin chimaeras, tetbot A and tetbot B, contain the tetanus 
toxin binding domain stapled with the proteolytic domain of botulinum 
neurotoxin A and B, respectively. The main difference between these 
chimaeras and the native toxins is that they are design to target IB4-negative 
DRG neurones, cleaving SNAP25 (tetbot A) (Ferrari et al. 2013) and VAMP2 
(tetbot B) (Appendix 2 & 4). Thus, targeting mainly peptidergic DRG neurones 
while maintaining the same proteolytic activity of the native toxins. Hence, in 
this chapter I aimed to explore the potential of these engineered toxins, tetbot 
 109 
A and tetbot B, to regulate peptide secretion and inhibit excitability changes 
induced by IS. 
 
5.2 Results 
5.2.1 Tetbot A cleaves SNAP25 in IB4-negative DRG 
neurones within 24 h incubation 
Tetbot A has been demonstrated to successfully cleave SNAP25 in 
hippocampal neurones and to be selective to IB4-negative DRG neurones 
(Ferrari et al. 2013). To assess the ability of tebot A to cleave SNAP25 in 
mouse DRG neurones in vitro, isolated DRG neurones were treated with 10 
nM tetbot A (concentration previously described in Ferrari et al. 2013) for 24 h 
and 65 h. Confocal microscopy of DRG neurones pre-treated for 24 h revealed 
robust staining of cleaved SNAP25 (cSNAP25) in IB4-negative DRG 
neurones’ soma and neurites (Figure 5.1 A). IB4-negative neurones were 
identified with IB4-FITC and cSNAP25 was identified by an in-house antibody 
selective only to the cleaved form of SNAP25 (Mangione et al. 2016). Western 
blotting further confirmed cleavage of SNAP25 within 24 h and 65 h (Figure 




Figure 5.1 Tetbot A selectively cleaves SNAP25 in mostly peptidergic DRG neurones.  
(A) Immunocytochemistry illustrating the selectivity of Tetbot A to IB4-negative DRG neurones. 
Cleaved SNAP25 signal was detected in the soma and neurites. (Blue) DAPI, identifying the 
nuclei, (Green) IB4, identifying non-peptidergic DRG population and (Red) cSNAP25. Scale 
bars show 10 µm. (B) Western blot depicting cleaved SNAP25 (with an anti-SNAP25 antibody 
with an epitope common to both cSNAP25 and SNAP25) in lysates recovered from matched 
cultures of DRG neurones treated for 24 h and 65 h with 10nM Tetbot A. Marta Alves Simões 
generated the western blot samples and Dr Charlotte Leese performed the western blot. 
 
 
5.2.2 Tetbot A reduces CGRP secretion 
To further understand the functional consequences of SNAP25 cleavage by 
tetbot A on DRG neurones, CGRP secretion was quantified from DRG 
neurones pre-incubated with 10 nM tetbot A and BoNT/A for 65 h (Figure 5.2 
A). Due to manufacture requirements tetbot A was dissolved in 0.4% n-
octylglucoside detergent (OG). Thus, all other groups were also incubated with 
the same concentration of OG. Conditions were optimised to trigger CGRP 
release specifically from IB4-negative neurones (capsaicin) versus CGRP 
release from unselected neurones (60 mM KCl) (further details Appendix 3). 
As shown in Figure 5.2, both stimuli effectively and significantly evoked CGRP 
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secretion (capsaicin, p=0.0095, N=6; KCl p<0.0001, N=3). In line with previous 
reports (Meng et al. 2009), I observed KCl to evoke more CGRP secretion than 
capsaicin; whether this was due to recruitment of peptidergic neurones not 
expressing the capsaicin receptor TRPV1 (Usoskin et al. 2015), or attenuated 
secretion caused by rapid desensitisation of the TRPV1 receptor under our 
experimental conditions (Jancso, Jancsoga.A and Szolcsanyi 1967) or more 
effective peptide secretion due to increased presence of full fusion events by 
KCl was not determined here.  However, importantly for the purposes of my 
study, pre-incubation with 10 nM tebot A significantly reduced KCl evoked 
CGRP secretion (p=0.0001, N=3) but not that induced by capsaicin (p=0.1388, 
N=4; Figure 5.2). Likewise, 10 nM BoNT/A did not reduce CGRP release 
induced by 1 µM capsaicin (p= 0.1372, N=4, one-way ANOVA with Fisher’s 





 Figure 5.2 Tetbot A reduces CGRP secretion from DRG neurones. 
Isolated DRG neurones were incubated with 1 µM capsaicin or 60 mM KCl in external 
recording solution for 30 min. The supernatant was used to detect CGRP levels using a 
commercial ELISA kit by Phoenix, USA. (A) DRG neurones in control conditions and pre-
incubated with vehicle (n-octylglucoside), 10 nM Tetbot A, and 10 nM BoNT/A. (B) DRG 
neurones pre-incubated with vehicle, Tetbot A for 24 h, and Tetbot A for 65h. One-way ANOVA 
with uncorrected Fisher’s LSD. [**p=0.0095 ***p=0.0003 (24 h) ***p=0.0001(65 h) 
****p<0.0001] (N=3-6 for each data column). Error bars show SEM. 
 
Next, a time-course analysis of 24 h and 65 h incubations was investigated 
(Figure 5.2 B). Pre-incubation with 10 nM tetbot A for 24 h and 65 h significantly 
reduced CGRP release induced by 60 mM KCl (24 h: p=0.0003, N=3; 65 h: 
p=0.0001, N=4). Surprisingly, no significant changes were seen with 1 µM 
capsaicin (24 h: p=0.085, N=3; 65 h: p=0.1388, N=4) when compared with 
basal release from cultures similarly pre-incubated with the toxins (24 h: 
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Hence, these data suggest that 10 nM tetbot A pre-incubation for 24 h is 
enough time for cleavage of SNAP25 that affects CGRP release. This could 
indicate that another t-SNARE is involved in secretion of CGRP (e.g. SNAP23) 
or that TRPV1 receptor is no longer coupled to the CGRP release. 
 
5.2.3 SNAP25 cleavage does not prevent 
hyperexcitability of DRG neurones in an in vitro model 
of inflammation 
After establishing that 10 nM tetbot A cleaves SNAP25 and inhibits CGRP 
release evoked by KCl within 24 h, I investigated whether the increased 
excitability induced by IS (Chapter 3) is also affected by SNAP25 cleavage. 
Hence, isolated DRG neurones were pre-treated with 10 nM tetbot A and 
control neurones with OG, followed by IS incubation for 6 h (Figure 5.3 A). 
Comparable to results reported in chapter 3 (Figure 3.3), the frequency of 
action potentials at rheobase and twice rheobase was assessed for the four 
groups (vehicle, IS, tetbot A, tebot A + IS) from IB4-negative DRG neurones 
(Figure 5.3). Surprisingly, vehicle treated DRG neurones showed an increase 
in baseline excitability together with DRG neurones pre-treated with tetbot A 





Figure 5.3 SNAP25 cleavage does not prevent hyperexcitability following 
inflammatory soup.  
(A) Isolated DRG neurones were pre-incubated with Tetbot A before adding the inflammatory 
soup (IS). (B) Representative traces of current clamp recordings at twice rheobase of DRG 
neurones of each condition. (C) Frequency of action potentials at rheobase and twice 
rheobase, (D) current threshold, and (E) resting membrane potential. Error bars show SEM in 
E and interquartile range for C and D. Each data point corresponds to a DRG neurone from 
up to five mice. *p<0.05 **p<0.01 ***p<0.001 kruskal-wallis test (nvehicle=20, nIS=9, nTetbotA=6, 
nTetbotA+IS=4, N=2-5). 
 
Tetbot A did not prevent hyperexcitability induced by IS. For all groups, with 
the exception of tetbot A only group, an increase excitability at twice rheobase 
was observed (Figure 5.3 C) (Median - vehicle rheobase: 2 Hz, vehicle twice 
rheobase: 11 Hz, p<0.05; IS rheobase: 2 Hz, IS twice rheobase: 16 Hz, 
p<0.01; tetbot A rheobase: 2 Hz, tetbot A twice rheobase: 19 Hz, p>0.05; tetbot 
A + IS rheobase: 2 Hz, tetbot A + IS twice rheobase: 18 Hz, p<0.001; Kruskal-
Wallis test, nvehicle=20, nIS=9, ntetbot A=6, ntetbot A + IS=4, N=2-5). In addition, no 
changes were seen in current threshold (Median - vehicle: 60 pA, IS: 55 pA, 
tetbot A: 85 pA, tetbot A + IS: 65 pA; kruskal-wallis test) (Figure 5.3 D) or 
resting membrane potential (vehicle: -61.67 ± 7.77 mV, IS: -57.25 ± 5.23 mV, 
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tetbot A: -58.67 ± 2.25 mV, tetbot A + IS: -58.5 ± 2.64 mV; one-way ANOVA) 
(Figure 5.3 E). Taken together, these data seem to suggest SNAP25 does not 
have a role in reducing or altering the effects of IS. 
 
5.2.4 The effects of tetbot B on VAMP1, VAMP2, and 
VAMP3 protein expression 
Another botulinum chimaera developed by the Davletov lab is tetbot B. Similar 
to tetbot A it also targets IB4-negative DRG neurones as it has the same 
receptor binding domain but instead has the proteolytic domain of BoNT/B 
(VAMP1/2/3 cleavage) and not BoNT/A. Previous unpublished lab data on 
cortical neurones has shown significant reduction in VAMP2 expression with 
10 nM Tetbot B (Appendix 2). To assess the effects of tetbot B on VAMP1, 
VAMP2 and VAMP3 protein levels in DRG neurones in vitro, isolated DRG 
neurones were incubated for 24 h and 65 h (Figure 5.4). Due to manufacture 
requirements tetbot B was also dissolved in 0.4% OG. Thus, control samples 
were also incubated with the same concentration of OG for 65 h. 
 
Figure 5.4 Tetbot B does not seem to significantly reduce VAMP1, VAMP2 or VAMP3 
after 24 h incubation. 
Isolated DRG neurones were incubated with 10 nM Tetbot B for 24 h and 65 h. (A) 
Representative immunoblots for VAMP1, VAMP2 and VAMP3. (B) Normalised expression to 
GAPDH loading control. The median intensity of the immunoblot bands indicating VAMP 
expression in DRG was divided by the median intensity of the respective loading control and 
then normalised to the experimental control (vehicle samples). VAMP1 – nvehicle=3, n24h=3, 
n65h=2; VAMP2 – nvehicle=4, n24h=4, n65h=2; VAMP3 – nvehicle=3, n24h=3, n65h=2. Error bars show 
SEM, no error bars were added to 65 h data points as the n number is insufficient. 
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Changes in protein levels were assessed by western blot via changes in band 
integrated density (Figure 5.4 A). The rationale behind these experiments was 
if Tetbot B cleaves VAMP1/2/3, the cleaved VAMP isoforms will be degraded 
by the cell and a decrease in protein expression may be detected via western 
blotting. At 24 h there were no significant changes detected (paired t-test; 
NVAMP1=3, p=0.471; NVAMP2=4, p=0.452; NVAMP3=3, p=0.561). At 65 h, both 
VAMP1 and VAMP2 seem to decrease in expression to 83% and 26% 
respectively but low N numbers did not allow to do further statistics (N=2) 
(Figure 5.4). 
 
5.2.5 Tetbot B does not impair CGRP secretion 
To evaluate tetbot B’s effects on CGRP secretion from DRG neurones, these 
were pre-incubated with 10 nM tetbot B or 10 nM BoNT/D (also VAMP 
cleaving) for 65 h and stimulated with 1 µM capsaicin or 60 mM KCl (Figure 
5.5 A). Akin to experiments with tetbot A, our control set significantly increased. 
That is, 1 µM capsaicin significantly increased the concentration of CGRP 
detected in vehicle treated DRG neurones’ supernatant (p=0.0095, N=6) as 
well as 60 mM KCl (p<0.0001, N=3), demonstrating that the stimuli are 
working. However, this increase was not prevented by pre-incubation with 10 
nM tebot B or 10 nM BoNT/D (1 µM capsaicin – control: 0.863 ± 0.572 ng/mL, 
vehicle: 1.2 ± 1.121 ng/mL, BoNT/D: 0.942 ± 0.257 ng/mL, tetbot B: 0.994 ± 
0.379 ng/mL) (60 mM KCl - control: 1.826 ± 1.235 ng/mL, vehicle: 2.565 ± 
1.124 ng/mL, tetbot B: 2.341 ± 1.176 ng/mL) (Figure 5.5 A), suggesting that 
cleavage of VAMP1/2/3 does not significantly impair CGRP secretion or that 




Figure 5.5 Tetbot B does not impair CGRP secretion from DRG neurones. 
Isolated DRG neurones were incubated with 1 µM capsaicin or 60 mM KCl in external 
recording solution for 30 min. The supernatant was used to detect CGRP levels using a 
commercial ELISA kit by Phoenix, USA. (A) DRG neurones in control conditions and pre-
incubated with vehicle (n-octylglucoside), 10 nM Tetbot B, and 10 nM BoNT/D. (B) DRG 
neurones pre-incubated with vehicle and Tetbot B for 24 h. (C) DRG neurones pre-incubated 
with vehicle and Tetbot B for 65h. One-way ANOVA with uncorrected Fisher’s LSD *p=0.0095 
****p<0.0001(N=3-6 for each data column). Error bars show SEM. 
 
Further analysis of CGRP secretion with tetbot B pre-incubation for 24 h and 
65 h (Figure 5.5 B and C) also showed no significant reduction for 24 h (1 µM 
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post hoc, p=0.998, N=3) (60 mM KCl – vehicle: 0.764 ± 0.343 ng/mL, tetbot B: 
1.07 ± 0.4 ng/mL, Tukey post hoc, p=0.963, N=3) and 65 h (1 µM capsaicin – 
vehicle: 1.2 ± 1.121 ng/mL, N=6, tetbot B: 0.994 ± 0.379 ng/mL, N=5, Tukey 
post hoc, p=0.188) (60 mM KCl – vehicle: 2.565 ± 1.124 ng/mL, tetbot B: 2.341 
± 1.176 ng/mL, Tukey post hoc, p=0.594, N=3). Thus, it suggests tetbot B has 
no effect on CGRP secretion form isolated DRG neurones when incubated for 
24 h or 65 h. 
 
5.2.6 Tetbot B does not reduce hyperexcitability of 
DRG neurones in an in vitro model of inflammation 
To further investigate the effects of tetbot B and the possible impact of 
VAMP1/2/3 cleavage on IS-induced hyperexcitability, I investigated the effects 
of tetbot B on DRG excitability (Figure 5.6 A). As reported earlier, vehicle 
treated DRG neurones had an unexpected high baseline excitability (Figure 
5.6 B and C) (rheobase: 2 Hz, twice rheobase: 11 Hz). Action potential 
frequency was significantly increased at twice rheobase (Kruskall-wallis with 
Dunn’s multiple comparisons test, p<0.05), defining them as hyperexcitable. 
IS alone and tebot B + IS also induced hyperexcitability characteristics (IS - 
rheobase: 2 Hz, twice rheobase: 16 Hz, Kruskall-wallis with Dunn’s multiple 
comparisons test, p<0.01) (Tetbot B + IS - rheobase: 2 Hz, twice rheobase: 15 
Hz, Kruskall-wallis with Dunn’s multiple comparisons test, p<0.05) (Tetbot B - 
rheobase: 2 Hz, twice rheobase: 12 Hz, Kruskall-wallis with Dunn’s multiple 
comparisons test, not significant). As with previous experiments with tetbot A 
no changes were also observed in resting membrane potential of DRG 
neurones (vehicle: -61.67 ± 7.77 mV, IS: -58 ± 7.56 mV, tetbot B: -60.2 ± 7.48 
mV, tetbot B + IS: -59.88 ± 8.23 mV; one-way ANOVA) (Figure 5.6 D) or current 
thresholds (Median - vehicle: 50 pA, IS: 50 pA, tetbot A: 95 pA, tetbot A + IS: 
140 pA; kruskal-wallis test) (nvehicle=20, nIS=9, nTetbotB=8, nTetbotB+IS=8, N=6) 
(Figure 5.6 E). ). Hence, these experiments may suggest that cleavage of 
VAMP1/2/3 does not have an impact on IS induced excitability but require 





Figure 5.6 Pre-incubation with 10 nM Tetbot B does not prevent IS-induced 
hyperexcitability. 
(A) Timeline for the experimental protocol. Isolated DRG neurones were pre-incubated 10 nM 
Tetbot B and with the inflammatory soup (IS) for 6 h or 10 nM Tetbot B only, IS or none. (B) 
Representative traces at twice rheobase for vehicle, IS, Tetbot B, and Tetbot B + IS.  (C) 
Frequency of action potentials at rheobase and twice rheobase, (D) current threshold, and (E) 
resting membrane potential. Error bars show SEM except (C) where median with interquartile 
range is plotted. Each data point corresponds to a DRG neuron from six mice. *p<0.05 




The aims of this chapter were to evaluate the potential of these new 
chimaeras, tetbot A and tetbot B, to inhibit CGRP release and to impair IS-
induced hyperexcitability. Using CGRP release as an assay to establish tetbot 
A and tetbot B functional effects, only tetbot A significantly reduced CGRP 
release within 24 and 65 h. Immunocytochemistry revealed strong staining for 
cSNAP25 in IB4-negative DRG neurones pre-incubated with tetbot A. Patch 
clamp analysis of the effects of pre-incubation of these chimaeras revealed no 
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significant changes in excitability. The DRG neurones incubated with either 
tetbot A or tetbot B had no significant changes in excitability parameters 
analysed. Vehicle effects were seen throughout patch clamping experiments 
that need to be addressed for further experiments. 
 
5.3.1 Tetbot A cleaves SNAP25 in IB4-negative DRG 
neurones within 24 h incubation 
These results further support previously published data (Ferrari et al. 2013) 
showing the efficacy and selectivity of tetbot A. Yet, this is the first time-course 
analysis done on DRG neurones. It strongly showed that 10 nM tetbot A 
cleaves SNAP25 within 24 h (Figure 5.1 A and B) which was maintained at 65 
h (Figure 5.1 B). The two bands detected by the anti-SNAP25 antibody (Figure 
5.1 B) are likely to be a consequence of the selectivity of tetbot A as it is only 
able to enter IB4-negative DRG neurones.  Thus, the uncleaved SNAP25 band 
is probably from IB4-positive DRG neurones and some IB4-negative DRG 
neurones. SNAP25 can be observed in IB4 positive neurones in cultures 
treated with tetbot A (Figure 5.1 A). 
 
5.3.2 Tetbot A reduces CGRP secretion 
Meng and colleagues have shown previously that SNAP25 is necessary for 
CGRP secretion in trigeminal ganglia neurones (Meng et al. 2009). In this 
chapter, pre-incubation with tetbot A reduced CGRP release from DRG 
neurones when stimulated with 60 mM KCl. Tetbot A and BoNT/A, used by 
Meng and colleagues, differ in their receptor binding domain (Ferrari et al. 
2013). Tetbot A has the receptor binding domain of the tetanus toxin, making 
it selective to mainly peptidergic DRG neurones, whereas BoNT/A does not 
selectively target this population. Unpublished lab data has shown that Tetbot 
A and BoNT/A overlap in their targeting DRG subpopulation but are not equal 
(due to different gangliosides). Hence, this would suggest that tetbot A has a 
higher degree of potency has it only targets mostly CGRP-secreting neurones. 
Yet, when 1 µM capsaicin was applied to both groups no significant changes 
were seen with pre-incubation of either these compounds. In similar 
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experiments by Meng et al. 2009, 10 nM BoNT/A pre-incubation has also been 
found to have limited effect in reducing CGRP secretion elicited by 1 µM 
capsaicin, around ~15%. Measurements obtained with tetbot A pre-incubation 
did not show a significant difference between 10 nM BoNT/A and 10 nM 
tetbotA. Both tendentially decrease, but it is not significant.  Hence, these data 
suggest that changes in the receptor binding domain do not have an impact 
overall in vitro CGRP release. However, this is likely to be due the potency of 
this compound rather than its selectivity. Furthermore, CGRP secretion elicited 
by 60 mM KCl had a 60% reduction with pre-incubation of 10 nM BoNT/A 
(Meng et al. 2007). Regrettably, no data were acquired for BoNT/A in our data 
set but tebot A did in fact significantly reduce CGRP release of DRG neurones 
elicited by 60 mM KCl.  
 
Usoskin and colleagues have shown that SNAP25 is present in peptidergic 
neurones expressing TRPV1 but only the subgroup PEP1 expresses both 
TRPV1 and CGRP (see introduction section 1.2.6). Hence, if tetbot A is able 
to enter these neurones it would cleave SNAP25 and impair SNAP25 mediated 
secretion in these neurones. Yet, the results in this chapter (Figure 5.2) do not 
show a significant reduction in CGRP secretion induced by capsaicin. If the 
expression analysis described by Usoskin et al. 2015 is true at the protein level 
it is possible that this assay is only targeting very small population and the 
results demonstrate a false negative. One possible improvement for this assay 
could be combined stimulation (capsaicin plus another stimulus) as half of the 
peptidergic population (PEP2) does not seem to express TRPV1. For instance, 
NGF has been shown to induce CGRP release from DRG neurones in culture 
(Park et al. 2010) and TrkA is expressed in both peptidergic subgroups. This 
might further explain why a significant reduction was seen only with unspecific 




5.3.3 SNAP25 cleavage does not prevent 
hyperexcitability of DRG neurones in an in vitro model 
of inflammation 
The rationale behind these experiments was to explore the reduction in 
mechanical hypersensitivity seen in vivo with tetbot A (Ferrari et al. 2013) and 
the role of vesicular fusion in establishing inflammatory hyperexcitability 
induced in our in vitro model (chapter 3). These data suggest that SNAP25 
has no role. One possible explanation would be that tetbot A may alter 
mechanosensitivity by decreasing the number of action potentials that lead to 
the release of neurotransmitters at the level of the spinal cord or by direct 
cleavage of vesicles containing neurotransmitters and ion channels at spinal 
cord synapses. In experiments with BoNT/A, pre-incubation with 10U/mL 
BoNT/A decreased the proportion of mechanosensitive DRG neurones 
showing slowly adapting currents (Paterson et al. 2014). In this in vitro model 
of inflammation, no changes in excitability were observed with the pre-
incubation of tetbot A. These are similar findings to those using BoNT/A 
(Paterson et al. 2014). Given the previous results with CGRP ELISA (Figure 
5.2) it is possible that the effects seen before (Ferrari et al. 2013) are mediated 
mainly by impaired neurotransmitter release at the level of the spinal cord from 
primary afferents and changes in mechanotransduction as seen with BoNT/A. 
Another possibility is that the targeting of mostly peptidergic DRG neurones by 
tetbot A in vivo impairs neurotransmitter release from IB4-negative DRG 
neurones at the level of the soma and that may affect mechanoceptors within 
DRG ganglia in a paracrine manner.  DRG neurones have been shown to 
secrete substance P, glutamate, and ATP from their soma (Jung et al. 2013, 
Zhang et al. 2007, Harding, Beadle and Bermudez 1999). For instance, Zhang 
and colleagues (2007) have shown that ATP secreted from DRG somata 
activates P2X7 receptors in satellite glial cells. In turn, they secrete TNF-α 
which increases DRG excitability. Evidence also suggests that parts of the 
botulinum and tetanus neurotoxins may be transcytosed to other cells even 
after internalization (Restani et al. 2012b, Restani et al. 2012a). BoNT/A has 
been found to cleave SNAP25 in neurones that were at least two synapses 
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away from the local injection site (Restani et al. 2012b), suggesting it can 
remain catalytically active between transcytosis and transport between 
neurones. Hence, in vivo effects can result from multiple affected cells. 
 
5.3.4 The effects of tetbot B on VAMP1, VAMP2, and 
VAMP3 protein expression 
Following unpublished lab experiments on cortical neurones, it was important 
to understand the effects of tetbot B on DRG neurones. Experiments on 
cortical neurones showed high efficacy of VAMP2 cleavage for tetbot B at 10 
nM after incubation for 65 h. Western blotting experiments on DRG neurones 
did not show a significant reduction in the intensity of either targeted VAMP. 
Regrettably, I did not acquire enough data points at 65 h but taken together it 
is likely that VAMP2 is cleaved by tetbot B at this time point in DRG neurones. 
This low N number was partially due to a high variability of data points collected 
for DRG neurones. Cortical neuronal preparations yield high number of 
neurones with a high concentration of VAMP2 (brain lysates versus DRG 
lysates in chapter 4, Figure 4.2) making it easier to prepare paired experiments 
(treated vs untreated). In addition, a higher expression of VAMP2 in cortical 
neurones may have contributed to more robust detection of changes with 
tetbot B with western blot experiments. 
 
5.3.5 Tetbot B does not impair CGRP secretion 
VAMP1 has been shown to mediate CGRP secretion of trigeminal ganglia 
neurones (Meng et al. 2007). Thus, given that tetbot B putatively targets IB4-
negative DRG neurones it was expected to reduce CGRP secretion further 
when compared to BoNT/D. BoNT/B and BoNT/D both cleave VAMP1/2/3 but 
BoNT/D has been shown to be more potent due to its higher uptake efficiency 
by neurones (Schiavo et al. 1992, Eleopra et al. 2013). Surprisingly, CGRP 
secretion stimulated with 1 µM capsaicin triggered similar CGRP release in 
vehicle, tetbot B and BoNTD treated groups (Figure 5.5). BoNT/D has been 
shown to reduce 1 µM capsaicin-induce CGRP release by 40% in trigeminal 
ganglia neurones. Conversely, BoNTB pre-incubation on trigeminal ganglia 
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neurones showed similar results to tetbot B (which have the same proteolytic 
domain), no reduction was seen when CGRP secretion was stimulated by 60 
mM KCl (Meng et al. 2007). Taken together, these data suggest possible 
differences in BoNT/D efficacy between trigeminal ganglia and DRG neurones. 
Experiments with increased concentrations of tetbot B will be useful to further 
determine its ability to cleave VAMP1/2/3 and affect CGRP release. However, 
there is still the underlying possibility that CGRP regulated exocytosis might 
be also mediated via other VAMP proteins. In chapter 4, all 7 isoforms were 
identified in DRG neurones and its further characterisation would be beneficial 
to understand if more than one VAMP drives CGRP release in DRG neurones.  
 
5.3.6 Tetbot B does not reduce hyperexcitability of 
DRG neurones in an in vitro model of inflammation 
Current clamp recordings suggest that cleavage of VAMP1/2/3 does not 
impact the effects of IS-induced excitability. Theoretically, this could be 
affected directly by altering the equilibrium of ion channels present at the 
plasma membrane responsible for DRG excitability. Or the impairment of 
neurotransmitter release by the targeted neurones could interfere with 
signalling and communication between the different cell types in vitro and 
affect the development of IS-induced hyperexcitability. However, no changes 
were observed.  There were two major caveats to these experiments. There 
was significant effect of the vehicle used. It had an impact on the excitability of 
the DRG neurones and CGRP secretion. Thus, it makes it more difficult to filter 
the effects of tetbot B (and tetbot A) on DRG excitability.  It is also possible 
that the efficiency of these chimaeras varies between cell types (cortical vs 
DRG neurones). The set concentration used for these experiments was 
originally established in cortical neurones (Appendix 2) and it could be that a 
higher concentration of tetbot B would be more suitable for DRG neurones. In 
fact, further experiments demonstrating the efficacy of this chimaera in DRG 
neurones should have been done at an earlier stage of the project to define 
better experimental conditions. 
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5.3.7 General discussion and future directions 
BoNT/A has been shown to silence synaptic transmission by cleaving SNAP25 
(Abrahamsen et al. 2008) and prevent trafficking of TRPV1 and TRPA1 in 
trigeminal ganglia neurones (Meng et al. 2009, Meng et al. 2016). Tetbot A 
and B are botulinum neurotoxin chimaeras that putatively target IB4-negative 
DRG neurones. In vivo analysis of the effects of tetbot A have shown reduction 
in mechanical hypersensitivity induced by CFA (Ferrari et al. 2013). Current 
clamp recordings from pre-treated DRG neurones with tetbot A and B have 
found no changes in excitability induced by IS. These are similar findings to 
those of BoNT/A. BoNT/A has been found to reduce mechanosensitivity and 
not to alter DRG excitability (Paterson et al. 2014). It is then possible that both 
tetbot A and BoNT/A alter the trafficking of a mechanotransduction channel 
responsible for slowly adapting currents. 
 
Yet, major technical issues were encountered during these acquisitions. The 
use of OG detergent to dissolve tetbot A severely decreased the success of 
patch clamp recordings and seems to independently increase DRG 
excitability. In fact, OG incubation also induced higher CGRP release from 
DRG neurones when compared to control (Appendix 3). Hence, it is possible 
that excitability effects of tetbot A are therefore clouded in this vehicle effect. 
Furthermore, the effects of this IS inflammation model are not fully understood 
(Chapter 3). It is possible that the combined effects of IS do not involve 
vesicular fusion of ion channels. Recordings from DRG neurones from mice 
treated with tetbot A and tetbot B would bypass this problem and is possibly 
the necessary step towards understanding both reduction of 




6 - General discussion 
 
In this thesis, I established an in vitro inflammation model which included an 
inflammatory soup (IS). This IS induced hyperexcitability in IB4-negative DRG 
neurones and an increase in TTX-R Na+ currents. One of the challenges of the 
interpretation of these results is the variety of mediators added and their effects 
on DRG neurones. As most inflammatory mediators interact with GPCRs, 
some studies have taken a broader approach in understanding nociceptor 
sensitisation during inflammation. Selective nociceptor Gaq, Ga11, and 
Gaq/11 knockout mice were used to understand the role of Gaq signalling on 
sensitisation. Gaq/11 knock out mice showed reduced sensitivity to inflammation 
in vivo induced by CFA, formalin, bradykinin and capsaicin (Tappe-Theodor et 
al. 2012). Interestingly, they also found that in untreated knock out DRG 
neurones the Gq/11 modulates the TTX-R Na+ currents. TTX-R currents were 
significantly increased at holding membrane potential between -20 and -10 mV 
whereas TTX-S currents were significantly increased between -30 and -10 mV. 
Thus, demonstrating a tonic role for GPCRs in DRG neurones and supporting 
previous research demonstrating the role of PKA and PKC in TTX-R current 
density (Gold et al. 1998). 
 
The physiological significance of these experiments is limited. The field of pain 
is remarkably complex due to the variety of pathologies and hallmarks. Given 
the broad range of inflammatory mediators added and the diversity of possible 
secretors of those, it is possible that the combination of these inflammatory 
mediators and the time window of these observations reveal a very specific 
set of excitability changes. Undoubtedly, any conclusions made are limited to 
these experimental parameters, but an in vitro model provides a powerful tool 
that can aid the understanding of the complex signalling such as those of pain 
and trafficking of VGSCs. 
 
In addition to increased excitability, the IS altered the expression levels of 
Nav1.7 and Nav1.9 at the plasma membrane. The plasma membrane of 
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neurones is a dynamic and heterogeneous ‘surface’ that determines the 
electrical capabilities of the neurones. Ion channels undergo highly dynamic 
changes such as lateral diffusion, endocytosis, clustering with other channels 
or receptors, and fuse in vesicles via exocytosis (Heine et al. 2016). One 
possible explanation for this observation is the change in subcellular location. 
It has been previously reported that changes in VGSCs density could have a 
significant impact of DRG excitability (Matzner and Devor 1992) and pain 
models have reported localised changes (Devor et al. 1993) or increase in 
expression of VGSCs (section 1.4.8). Hence, it suggests a role in dynamic 
assembly of VGSCs to tune responses. One striking example of a local 
interaction has been reported in cardiac myocytes (Dixon et al. 2015). Local 
interaction of Cav1.2 calcium channels via C-termini determines the size of 
calcium responses and it is essential for the excitation-contraction coupling of 
the cardiac myocytes. This amplified calcium current persists longer than the 
initial current that elicited it and may reflect “molecular memory”. Thus, it 
establishes lasting changes in excitability. These advances in single particle 
trafficking are then an appealing method to understand VGSCs relocation in 
pain pathologies. For example, the tuning of action potential firing in DRG 
neurones in disease and questions of how the channels are inserted into the 
membrane could be elucidated.  
 
This study demonstrates for the first time the VAMP isoforms expressed in 
DRG neurones: VAMP1-5, VAMP7 and VAMP8. Considering what has been 
reported in the CNS, different VAMPs are reported in different neurotransmitter 
release pathways (Pratt et al. 2011, Ramirez and Kavalali 2011), it is likely that 
DRG neurones use different VAMP isoforms for vesicular pools that are 
triggered by different mediators. For instance, VAMP2 mediated exocytosis 
form the majority of the evoked neurotransmitter release in central synapses 
(Sudhof and Rothman 2009). Yet, VAMP2 knock out neurones still show 
spontaneous neurotransmitter release (Schoch et al. 2001). Other VAMPs 
were found in central synapses at lower levels such as VAMP4 and VAMP7 
(Takamori et al. 2006). Reelin, a glycoprotein, was found to elicit the fusion of 
VAMP7-containing vesicles and thus enhancing neurotransmission (Bal et al. 
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2013). On the other hand, VAMP4 has been described in a distinct vesicular 
pool side by side with VAMP2, suggesting that they both are trafficked 
independently to the synapse and mediate neurotransmission but form 
independent SNARE complexes (Raingo et al. 2012), proposing that synapses 
diversify their release properties by using different SNARE proteins. In the 
context of this thesis, VAMP1, 2 and 7 were observed in the neurites, 
suggesting a role in neurotransmission or neurite outgrowth (Gupton and 
Gertler 2010). In addition, VAMP7 was only found in DRG neurones which 
could indicate a neuron-specific role. Hence, exploring the functional roles of 
the VAMPs identified in this thesis can provide a molecular insight to the 
distinct responses nociceptors demonstrate to different pain conditions. 
 
In this thesis, Nav1.7 was not found to co-localise with VAMPs. This is likely a 
false negative as most of the Nav1.7 was found at the plasma membrane and 
not being trafficked. Unfortunately, due to time constraints, I did not complete 
the same set of experiments in the presence of the IS, a likely stimulant for 
vesicles containing Nav1.7 to fuse with the plasma membrane. Another 
approach could be the use of PKA or PKC activators as these have been 
shown to modulate Na+ current density in DRG neurones (Liu et al. 2010, Lu 
et al. 2010, Gold et al. 1998). In addition, once an established model for the 
fusion of vesicles containing Nav1.7 (or other a-subunits) with the plasma 
membrane, botulinum neurotoxins or chimaeras could be added to identify 
SNARE proteins interacting with this membrane fusion. 
 
In light of these putative differences in vesicular pools within DRG neurones, 
botulinum neurotoxins were developed to both target a specific DRG 
population subset, IB4-negative, and to cleave a specific SNARE. At this 
stage, tetbot A seems to effectively reduce CGRP secretion, confirming similar 
results with BoNT/A in trigeminal ganglia (Meng et al. 2007). Likewise, it does 
not alter the excitability which is in agreement with previous results with 
BoNT/A (Paterson et al. 2014) or IS-induced hyperexcitability. Key 
experiments to follow these findings would be measuring the Na+ current in the 
presence of either tetbot A or tetbot B pre-incubation and then an inflammatory 
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insult. Due to the technical issues found during this set of experiments was not 
acquired. One solution could be via the injection of the chimaeras to the mouse 
hind paw (as described in Ferrari et al. 2013) before culturing and adding IS, 








Appendix 1 – Nav1.7, Nav1.8 and 
Nav1.9 in cortical neurones 
 
Cortical neurones have been described to not express Nav1.7, Nav1.8 and 
Nav1.9 (Lai and Jan 2006). To evaluate the specificity of the antibodies used 
in this thesis, cortical neuronal cultures were probed with antibodies against 
these a-subunits. No immunofluorescence was detected (Figure A1.1). 
 
Figure A1.1 Nav1.7, Nav1.8 and Nav1.9 in embryonic cortical neurones in culture.  
Cortical neurones were isolated from E17.5 rats (dissection and isolation by Dr Claudia Bauer).  
In red, b-III tubulin; In green, VGSCs a-subunits; In blue, nuclei. Control here is defined as a 
no primary antibody control. Scale bar shows 30µm.  
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Appendix 2 - Cleavage of VAMP2 by 
Tetbot B and 2x Tetbot 
 
 
Figure A2.1 Cleavage of VAMP2 by Tetbot B and 2x Tetbot. 
Cultures of rat cortical neurones were treated with a range of concentrations for tetbot B (the 
construct used in this thesis, named 1xTBD-lcTd/B) and 2xTBD/LcTd/B for 65 h. Lysates of 
these cultures were used to identify the percentage of uncleaved VAMP2 and syntaxin 1 as 
loading control. The concentration of tetbot B used in this thesis was 10 nM. All experiments 
and analysis executed by Dr Charlotte Leese.  
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Appendix 3 - CGRP release from DRG 
cultures treated with OG and RBDT 
 
 
Figure A3.1 CGRP release from DRG cultures treated with OG and RBDT.  
Isolated DRG neurones were incubated with 1 µM capsaicin or 60 mM KCl in external 
recording solution for 30 min. The supernatant was used to detect CGRP levels using a 
commercial ELISA kit by Phoenix, USA. DRG neurones in control conditions, pre-incubated 
with vehicle (n-octylglucoside), and the receptor binding domain only of tetbot (RBDT). One-
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Appendix 4 – Botulinum neurotoxins 
and chimaeras cleavage sites 
 
Figure A4.1 VAMP cleavage sites.  




Figure A4.2 SNAP25 cleavage sites. 
Botulinum neurotoxins is depicted in yellow/green (A). A black underscore demonstrates 
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